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ABSTRACT 
 
Individuals that carry deleterious mutations in the breast and ovarian cancer 
susceptibility gene 1 (BRCA1) have much more elevated risk to develop breast and/or 
ovarian cancer than the individuals from the general population. The BRCA1 gene 
product has been implicated in several aspects of the DNA damage response, but its 
biochemical function in these processes has remained elusive. In order to probe BRCA1 
functions we conducted a yeast two-hybrid screening to identify interacting partners to a 
conserved motif (Motif 6) in the central region of BRCA1. In this dissertation, we report 
the identification of the actin-binding protein Filamin A (FLNA) as a BRCA1 partner and 
demonstrate that FLNA is required for the efficient regulation of DNA repair process at 
its early stages. Cells lacking FLNA display a diminished ionizing radiation (IR)-induced 
BRCA1 focus formation and a slow kinetics of Rad51 focus formation. In addition, our 
data demonstrate that FLNA is required to stabilize the interaction between DNA-PK 
holoenzyme components such as DNA-PKcs and Ku86 in a BRCA1-independent 
manner. Our data are consistent with a model in which the absence of FLNA 
compromises homologous recombination and non-homologous end joining. Our findings 
have implications for our understanding of the response to irradiation-induced DNA 
damage.  
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INTRODUCTION 
 
BRCA1 and Cancer Predisposition 
 
Hereditary Predisposition to Breast and Ovarian Cancer 
 
According to the American Cancer Society, 207,090 women and 1,970 men were 
diagnosed with breast cancer in 2010 in the US alone. Moreover, breast cancer is among 
the most frequent malignancies affecting women worldwide. Germline mutations in the 
breast and ovarian cancer predisposition gene 1 (BRCA1) are responsible for the majority 
of early-onset breast and ovarian cancers arising in families with multiple cases. 
Furthermore, it has been shown that mutations in BRCA1 and BRCA2 genes occur with 
frequency of 1:250, which translates into 250 000 women in the US who are carriers [4]. 
Therefore, it is crucial to identify individuals at risk early. These individuals and their 
families have the options of increased surveillance, chemoprevention, or prophylactic 
surgeries, all of which can potentially reduce the possibility of developing cancer. 
 The cloning of BRCA1 made early identification of individuals at risk possible by 
genetic testing. However, there are many difficulties that leave around 10% of the women 
who undergo testing with uninformative results due to the finding of BRCA1 variants for 
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which the cancer association is not known. These variants are called variants of uncertain 
significance (VUSs). Moreover, in minority populations the percentage of women, 
receiving uninformative results is significantly higher (35-50%) making it a health 
disparity issue that needs to be addressed. These women do not have all the information 
to make informed clinical decisions. In addition, BRCA1 is inactivated in some sporadic 
breast cancer cases, suggesting an important role for BRCA1 in breast cancer in general. 
As far as its presentation in families, breast and ovarian cancer can be considered 
as hereditary, familial, or sporadic. Ascertainment criteria for hereditary (inherited) 
breast and/or ovarian cancer syndrome often include but are not limited to: early age of 
cancer onset, multiple affected individuals within a family, development of bilateral 
disease, and male individuals with breast cancer. Hereditary breast and ovarian cancer 
cases have strong family history for the disease and can often be attributed to mutations 
in genes such as BRCA1 and BRCA2. In familial cancer, there is a pattern in the family, 
pointing a hereditary component. However, these cases have not been ascribed to 
mutations in any of the known genes. Sporadic cancer can be defined as a type of cancer, 
which arises in individuals that usually do not have family history, and the disease has 
not been attributed to any known genetic factor. However, we should point out that this 
classification is arbitrary and is often difficult to make a clear-cut distinction between 
different classes.   
In this thesis, we focus on BRCA1 syndrome, which is defined as an ―inherited 
tumor syndrome with autosomal dominant trait and markedly increased susceptibility to 
breast and ovarian tumors, due to germ line mutations in the BRCA1 gene. Additional 
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organ sites include colon, liver, endometrium, cervix, fallopian tube and peritoneum‖ [5]. 
It is estimated that 5-10% of all breast cancer cases are hereditary (Figure 1). 
Approximately 30-45% of the hereditary cases can be attributed to BRCA1 and BRCA2 
mutations [6].  
According to our current understanding, hereditary breast cancer can be assigned 
to three groups of susceptibility alleles: genes that have high (e.g. BRCA1 and BRCA2), 
moderate (e.g. ATM, BRIP1, CKEK2, and PALB2), and low penetrance alleles (e.g. 
FGFR2, TNRC9, and MAP3K1) [7].  
 
Early Findings in Hereditary Breast and Ovarian Cancer 
 
The first report about hereditary breast cancer dates back to 1866. It was made by 
the French surgeon Paul Broca [8] who reported that in five generations of his wife’s 
family 10, out of the 24 women died from breast cancer [8]. Another important discovery 
in breast cancer research happened in 1950, when Gardner and Stephens examined 668 
individuals from a Utah family. Their findings showed that the frequency of breast cancer 
was 20 times higher in that family than in the general population of Utah over the age of 
30 [9]. The researchers concluded that ―the heredity is a predisposition for breast cancer, 
but the nature of the inheritance is not known‖ [9].  
The ―nature of inheritance‖ became the focus of subsequent studies on breast 
cancer. These studies explored the role of environment and family history in breast  
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Figure 1. Breast cancer susceptibility genes. Hereditary breast cancer accounts 
for 5-10% of all breast cancer cases. BRCA1 and BRCA2 are responsible for 
approximately 30-45% of hereditary breast cancer cases. Mutations in ATM, CHK2, 
PTEN, PALB2, RAD50, NBS1, BRIP1, and TP53 explain some of the remaining 
cases. The rest of the hereditary cases have not been attributed to the any known 
susceptibility genes. (Adapted from [1]). 
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cancer predisposition. Therefore, Lynch and colleagues decided to study 34 families, 
purposefully selected because they had two or more members affected with breast cancer. 
Their findings showed that in some of those families the significant predisposition was 
not only for breast cancer, but also for other malignancies [8]. They concluded that 
multiple factors including interactions of different genetic and environmental factors 
could contribute to cancer predisposition [8]. 
Further, Newman et. al analyzed data from 1579 families with multiple breast 
cancer cases. Based on this analysis, the researchers offered a model for the explanation 
of the breast cancer frequent occurrence in the participants’ families [10]. According to 
that model, inherited breast cancer predisposition was caused by an autosomal dominant 
allele with high but incomplete penetrance [10]. That study was followed by mapping the 
gene responsible for early onset breast cancer to chromosome 17q21 [11, 12]. Finally, the 
seminal discovery on hereditary breast and ovarian cancer happened in 1994, when the 
first breast and ovarian cancer susceptibility gene BRCA1 was cloned [13]. 
 
Breast and Ovarian Cancer Risk Associated with BRCA1 
 
Germline mutations in BRCA1 are responsible for 30-45% of all hereditary breast 
cancer cases and around 80% of the cases that have multiple breast and ovarian cancers 
[14]. Therefore, BRCA1 is the major locus responsible for the breast and ovarian cancer 
predisposition. The lifetime risks for developing breast and ovarian cancer in the general 
population are estimated to be 12.7% and 1.3% respectively (American Cancer Society 
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2010). Meanwhile, women who carry deleterious mutations in BRCA1 have the lifetime 
risk of developing breast cancer of 36-82% and 16-49% for ovarian cancer (Table 1). The 
wide range of those risk estimates can be explained by differences in the study design, 
populations, and the age limit used to calculate lifetime risk (Table 1). Nevertheless, the 
risk for women who are carriers of deleterious mutations in BRCA1 to develop breast 
and/or ovarian cancer is five to ten times higher than the risk for the women in the 
general population. Finally, deleterious mutations in BRCA1 are accepted to be the best-
known predictor for breast cancer risk [15, 16].  
 
Table 1. Lifetime risk for breast and ovarian cancer among carriers of BRCA1 
mutations. 
 
Breast cancer risk % Ovarian cancer risk % Additional information Refs 
65 39 Combines 22 studies [17] 
69 49 AJ (Ashkenazi Jewish) [18] 
43-67 14-33 AJ [19] 
36  AJ [20] 
82  Selection for strong family history [14] 
 37 AJ [21] 
68 36 Patients diagnosed with ovarian 
cancer in Ontario, Canada 1995-96 
[22] 
46  AJ [23] 
56 16 AJ [24] 
59.9  AJ, unselected for family history [25] 
72.8 40.7 Risk, estimated up to the age of 70 [26] 
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In contrary, in sporadic breast and ovarian cancer cases the situation is different: 
somatic BRCA1 mutations are rare [27, 28] but epigenetic inactivation by promoter 
hypermethylation [29-31] or decreased expression of BRCA1 [32, 33] have been found in 
sporadic tumors. This suggests that BRCA1 may also play a role in sporadic breast and 
ovarian cancer development. 
 
Contribution of BRCA1 to Breast and Ovarian Cancer 
 
Breast cancer is a heterogeneous disease.  Based on gene expression patterns, it 
can be classified into five distinct groups: luminal A and B, normal breast like, ERBB2, 
and basal-like breast carcinomas [34]. The majority of BRCA1-related breast tumors can 
be classified as basal-like type breast carcinomas [34, 35]. The analysis of gene 
expression profiles of BRCA1-related breast tumors led to the conclusion that they are 
more likely to be estrogen receptor alpha negative, progesterone receptor negative, and 
Her2/neu negative than the sporadic ones [34-37] (also referred as triple-negative breast 
cancer). Moreover, mutations in TP53 are more frequent in BRCA1-related breast tumors 
than in the sporadic ones [38, 39]. Strikingly, triple negative breast cancer occurs more 
frequently in pre-menopausal African-American women when compared to the age-
matched female white Americans [40]. Finally, triple negative breast cancer in African-
Americans phenotypically share the same characteristics as BRCA1-related breast cancer 
[40]. 
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Similar to the studies on the breast cancer, attempts have been made to classify 
ovarian tumors using a gene expression profile [41]. Unfortunately, the sample size of 
these studies was small. Therefore, they did not have sufficient statistical power, which 
precluded the classification of ovarian cancer. Based on histology, over 90% of BRCA1-
linked ovarian tumors are serous adenocarcinomas [42].   
 
BRCA1 Is a Tumor Suppressor Gene 
 
Inheritance of one defective BRCA1 copy is enough to cause cancer 
predisposition, but in order for cancer to develop, the remaining wild type allele needs to 
be inactivated [43]. Therefore, BRCA1 fulfills the classic ‖two-hit hypothesis‖ definition 
for the tumor suppressor gene: both alleles are inactivated in cancer [44]. In addition, 
mouse models support the fact that BRCA1 is a tumor suppressor. Although inactivation 
of both Brca1 alleles causes embryonic lethality [45-48], specific inactivation of Brca1 in 
mammary gland cells leads to the tumor development [49-52].  Interestingly, unlike 
heterozygous women, heterozygous mice did not develop tumors [51]. However, 
mammary tumors resembling the basal-like breast tumors of BRCA1 mutation carriers 
were detected after conditional inactivation of Brca1 in the mammary glands [50, 51, 53]. 
A summary of Brca1-related mouse models and their phenotypes is shown on Table 2.  
In contrast to conditional mouse models developed to study the role of BRCA1 in 
breast cancer, there are very few mouse models on the ovarian cancer progression [54-
56]. In the first mouse model for Brca1-linked ovarian cancer, Brca1 was conditionally 
9 
 
inactivated in the ovarian granulosa cells [54]. The mice developed cystic tumors, which 
are thought to precede ovarian cancer [54]. Such tumors carried normal Brca1 alleles, 
which indicated a paracrine mechanism in ovarian cancer development-Brca1 influences 
tumor development in the ovarian surface epithelium indirectly through granulosa cells 
[54].  
 
Table 2. Mouse models for BRCA1 deficiency (adapted from [57]) 
Allele Phenotype Cre-transgene Refs 
Brca1
ex2
 death at e7.5  [47] 
Brca1 
5-6
 death at e7.5  [45] 
Brca1 
11-
 death at e7.5-9.5  [58] 
Brca1 
223-763
 death at e10-13.5  [48] 
Brca1 
ko
 death at e7.5-8.5  [46] 
Brca1 
S971A
 none  [52] 
Brca1
Tr
 lymphomas, sarcomas, breast 
cancer 
 [59] 
Brca1 
1700T
 death at e10.5  [60] 
Brca1 
F5-6
 thymocyte specific  Lck-Cre [61] 
Brca1 
Co/
 death at e12.5  [49] 
Brca1 
11
 lymphoma, ovarian tumors  [62] 
Brca1
F11/F11;p53+/-
 mammary tumors MMTV-Cre or WAP-
Cre 
[63] 
Brca1
F11/F11;p53F5-6/p53F5-6
 mammary tumors WAP-Cre
c [64] 
Brca1
F22-24/F22-24;p53+/-
 basal-like breast cancer BLG-Cre [50] 
Brca1
F5-13/F5-13;p53F2-10/F2-
10
 
basal-like breast cancer K14-Cre [53] 
Brca1
F2/F2
 basal-like breast cancer WAP-Cre [51] 
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In the other mouse model, Brca1 was inactivated in the ovarian surface epithelial 
cells, which resulted in pre-neoplastic changes, but not ovarian cancer [56]. In 
conclusion, it is not known how well these models represent the ovarian cancer in 
humans, and the role of BRCA1 in the transformation of ovarian surface epithelial cells is 
unclear. Nevertheless, the Brca1-related mouse models support the evidence that BRCA1 
is a tumor suppressor gene and set the stage for studying the mechanisms by which 
BRCA1 suppresses tumor formation at the organism level. 
 
Spectrum of Mutations in the BRCA1 Gene 
 
The mutation spectrum of BRCA1 varies in different populations. For example, 
genetically heterogeneous populations such as those in the United States, the United 
Kingdom, and Canada display big differences in documented BRCA1 mutations 
(reviewed in [4] [6]). On the other hand, in geographically or historically isolated 
populations like Icelanders or Ashkenazi Jews, the majority of hereditary breast and 
ovarian cancer can be attributed to founder mutations [6]. Founder mutations are specific 
mutations that appear repeatedly in ethnically defined groups because of genetic drift [4]. 
For example, three founder mutations in BRCA1 (185 delAG, HGVS nomenclature 
NC_000017.9:g.38529572_ g.38529571delAG and 5382 insC, NC_000017.9: 
g.38462606dupC) and BRCA2 (6174 delT, NC_000013.9:c.24822delT) genes are 
responsible for most of breast and ovarian cancer cases in individuals from Ashkenazi 
Jewish descent [65]. Founder mutations in BRCA1 have also been found in populations 
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from Germany, Norway, Poland, and Sweden [6]. The identification of founder mutations 
facilitates genetic testing for hereditary breast and ovarian cancer in the studied 
populations by decreasing the cost and the time of the test.  
 
Genetic Testing for BRCA1 and the Variant of Uncertain Significance (VUS) Problem 
 
The cloning of BRCA1 and BRCA2 made the early identification of individuals at 
risk possible by standard genetic testing [13] [66] [67], which is done by direct 
sequencing [68]. The results of genetic testing influence clinical decisions such as 
increased surveillance, prophylactic surgery, chemoprevention, and response to therapy 
(both radiation and chemotherapy). In the US, genetic testing for BRCA1 and BRCA2 is 
done by Myriad Genetics Laboratories and has three outcomes: 
(1) Negative ("No mutation detected" or "Favor polymorphism"). In the case of 
BRCA1, this means that no cancer associated (deleterious) mutation was detected. This 
result is informative for the proband, only if a BRCA1 mutation is found in other affected 
family members. In this case, it excludes the person that is undergoing testing. However, 
it is important to point out that a negative result can be due to changes that cannot be 
detected by direct sequencing such as large rearrangements that lead to deletion of whole 
exons and mutations in the regulatory regions [69]. For these cases, there is an additional 
test that can be applied, called BART (BRCAanalysis Rearrangement Test), which tests 
for a panel of rearrangements in BRCA1 and BRCA2 genes. Another possible reason for 
an individual with a family history of breast and ovarian cancer to get a negative result is 
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that the family might have a mutation in other breast cancer predisposing genes such as 
CHEK2 and ATM [69]. A recent study has revealed that even when first-degree relatives 
of women, carriers of BRCA1 or BRCA2 mutations, are tested negative for the same 
BRCA1 and BRCA2 mutations, those relatives are still at increased risk of cancer [70]. 
(2) Positive ("Positive for a deleterious mutation" or "Suspected deleterious"). In 
this case, the risks for the individual to develop breast and ovarian cancer are much 
higher than the risk for the general population (Table1). 
(3) Uncertain ("Genetic change of uncertain significance"). This result means a 
genetic change in BRCA1 for which the impact on protein function has not been 
determined. These genetic changes are called unclassified variants or genetic variants of 
uncertain clinical significance (VUSs). It is estimated that around 10% of Caucasians, 
35% of Hispanics, and up to 50% of African Americans undergoing testing receive VUS 
results [71-73]. Considering over 1500 different alleles of BRCA1 in the human 
population (Breast cancer information core http://research.nhgri.nih.gov/projects/bic as of 
3.9.11) and the rarity of the individual alleles, one of the most challenging tasks for 
clinical genetics is to distinguish which are benign and which are cancer predisposing. 
These three outcomes are similar for BRCA2 testing.  
 
How to Determine the Association of a Genetic Variant with a Disease? 
 
There are two methods that can be used for determining association of a genetic 
variant with a disease (cancer). The first method is defined as genetic i.e. testing co-
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segregation between the variant and the disease in families, in which this variant has been 
found. The second method is epidemiological i.e. comparing the frequency of a given 
variant between two groups. These groups are cases (individuals from different families 
that have the disease) and controls [74]. In the case of BRCA1 VUSs, both methods have 
limitations.  
The genetic method cannot always be applied because usually the families are 
small, the number of genotyped family members is limited, and there is an uncertainty 
about which type of cancer (diagnosis, histology, ext.) a deceased or distant family 
members presented. The epidemiological method relies on relatively common alleles, but 
individual VUS are very rare in the population. To overcome this problem, several 
methods to help classify the VUSs have been proposed: 
1. Functional assays to test the effect of amino acid change on the function 
of BRCA1: 
1.1 Transcription activation assay [75, 76] and reviewed in [77] 
BRCA1 C-terminus functions as an activator of transcription [78, 79] when 
expressed as a fusion with the heterologous DNA binding domain. Cancer 
predisposing mutations in this region of BRCA1 impair this transcriptional 
activity, whereas benign polymorphisms show similar activity as the wild type 
BRCA1 [80, 81]. This fact served as the basis for the development of the 
transcription activation assay, which can test the integrity of BRCT domains and 
its neighboring regions at the BRCA1 C terminus. This assay is limited to the C-
terminal mutants of BRCA1. 
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1.2 Yeast small colony phenotype assay [82, 83]  
Yeast small colony phenotype is based on the premise that constructs, which 
contain the C terminus of BRCA1, inhibit the yeast growth when expressed. This 
assay is limited to the C terminus of BRCA1. 
1.3 E3-ubiquitin ligase activity assay [84] 
The BRCA1/BARD1 heterodimer displays an E3 ubiquitin ligase activity [85]. 
Therefore, functional assays have been developed to test BRCA1 variants for their 
ability to bind to BARD1 and UBCH5A (the E2 ubiquitin conjugating enzyme). 
In addition, such functional assays test BRCA1 in vitro E3 ligase activity. This 
assay is domain specific and can test variants only in the N terminus of BRCA1. 
1.4  Phosphopeptide binding assay  
Phosphopeptide binding assay evaluates the ability of BRCT domains to interact 
with a phosphopeptide from BACH1 protein. This assay is also limited to the 
BRCT domains of BRCA1 [86]. 
1.5 Protease sensitivity assay  
Protease sensitivity assay tests for the stability of BRCT domains upon cleavage 
with protease. Some subtle deleterious changes in BRCA1 may not be detected 
when using this assay [86] . 
1.6 Yeast recombination assay  
Yeast recombination assay tests for BRCA1 C-terminus variants effect on the 
recombination between the yeast HIS3 and ADE2 loci. This type of assay is 
restricted to the BRCT domains [87]. 
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1.7 Human BRCA1 BAC reconstitution into mouse embryonic stem cells, 
which have conditional Brca1 allele, followed by functional tests for cell 
viability, DNA repair, and mammary gland carcinogenesis [88]. The same 
approach can be used to rescue embryonic lethality into nullizygous for the mouse 
Brca1 allele embryos [88].  
2. Co-occurrence in trans with a deleterious mutation. This method is 
based on the observation that some functions of BRCA1 are essential for early 
development.  For example, homozygous truncating mutations in BRCA1 are 
embryonic lethal in mice [45, 46]. Moreover, so far no patient has been reported 
having two deleterious mutations in BRCA1 gene [89]. Thus, this method is based 
on the hypothesis that homozygosity for deleterious mutations is either embryonic 
lethal or lead to recognizable phenotype [90]. If a certain VUS of BRCA1 co-
occurs with a known deleterious mutation in one tested individual, most likely 
this VUS is a benign polymorphism. 
3. Bioinformatics methods is a structure based analysis, applied to generate 
computation prediction models [91, 92] and analysis of BRCA1 sequence 
conservation among different species and the amino acid characteristics [93-95]. 
All the methods mentioned above have their own assumptions, advantages, and 
disadvantages. Therefore, none of these methods should be used alone to determine the 
disease association of VUSs or as a clinical application. In addition, several attempts 
have been made to combine different sources of data to classify VUS [91, 95-97]. Even 
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after using multiple sources of data, the classification of VUSs is far from being directly 
applied in the clinic, which is the ultimate goal of any research on the VUSs of BRCA1. 
To address this problem and to improve the clarity in conveying the information 
from genetic testing to the patients, the scientific community recommends the usage of a 
five-scale classification, which includes the information about how relevant the particular 
BRCA1 variant is for the clinical practice [98]. According to this scale, the results from 
the genetic testing for BRCA1 and BRCA2 mutations can fall into one of the five 
categories [98]. 
 Class 1 corresponds to “not pathogenic/no clinical significance‖ or ―no clinical 
significance‖ variants. Likelihood for a variant to be pathogenic in this category is below 
0.1%. 
Class 2 corresponds to ―likely not pathogenic/little clinical significance‖ variants.  
Likelihood for a variant to be pathogenic in this category is between 0.1 and 5%.  
Class 3 corresponds to  ―variants with uncertain clinical significance‖. Likelihood 
for a variant to be pathogenic in this category is between 5 and 95%. 
Class 4 corresponds to ―likely pathogenic‖ variants. Likelihood for a variant to be 
pathogenic in this category is between 95 and 99%. 
Class 5 corresponds to ―definitely pathogenic‖ variants. Likelihood for a variant 
to be pathogenic in this category is above 99%. 
Each of these classes is accompanied by recommendations for treatment and 
surveillance options. As more patients are tested and the methods for classification are 
improving, fewer variants will fall into Class 3 [98]. Therefore, the results from the 
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functional assays can be a valuable addition for clinical geneticists when advising their 
patients. Importantly, the accumulated knowledge on functional assays to classify alleles 
of BRCA1 and BRCA2 can be applied to any other disease-predisposing gene.  
In summary, information for BRCA1or BRCA2 status is the most predictive factor 
for the risk of breast and ovarian cancer development. The increase in risk is substantial 
and is almost five to ten times higher than the risk in the general population. Moreover, 
deleterious mutations in the BRCA1 gene have high penetrance, and the patients’ 
response to treatment is highly influenced by their BRCA1 status. However, despite the 
enormous efforts to classify VUSs and to help patients with their clinical decisions, our 
ability to identify at-risk women remains problematic. One of the main limitations is the 
lack of knowledge about mechanistic aspects of BRCA1 biology. BRCA1 is a protein 
with pleiotropic functions, and it is not known how many of those functions alone or in 
combination contribute to the functions of BRCA1 as a tumor suppressor. To bridge the 
gap between the lack of understanding of BRCA1 role in tumor suppression on one hand 
and the ability to classify the BRCA1 VUSs on the other, we set out to systematically 
evaluate the biochemical function of BRCA1 domains and motifs. In this dissertation, we 
focus on analyzing the function of two BRCA1 conserved motifs called Motif 2 and 
Motif 6. 
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Why Are Studies on BRCA1 Important? 
 
Mutations in BRCA1 and BRCA2 are responsible for 5-10% of all breast cancer 
cases. A common critique to studies on BRCA1 is that a relatively small number of 
women with inherited mutations of BRCA1 limit their impact on the disease burden. 
Then, why should we study BRCA1? To summarize, the studies on BRCA1 are important 
for the patients that carry deleterious mutations in BRCA1 and their families 
because of the following reasons: 
1. Early detection of individuals at-risk is important so that they and their 
families can make informed clinical decisions about prophylactic surgery, increased 
surveillance, chemoprevention, and risk for other malignancies. The presence of harmful 
BRCA1 mutation in a family influences other decisions in life such as childbearing. 
2. Individuals that have already developed breast cancer and have deleterious 
mutation in BRCA1 will respond differently to radiotherapy and chemotherapy than the 
individuals from the general population. 
Moreover, studies on BRCA1 have much broader implications, because: 
1. Approximately 10% of all genetic tests find VUS (this percentage is higher in 
some populations, see page 2), which translates into the fact that ~ 10 000 families in the 
US alone, cannot make informed clinical decisions. 
2. BRCA1 is epigenetically silenced in sporadic tumors [27, 32] and may regulate 
mammary stem/progenitor cell fate [99, 100]. 
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3. Many genes implicated in breast cancer function in DNA damage response 
pathways. Thus, an understanding of BRCA1 role will likely have an impact on other 
forms of breast cancer not attributable to germline mutations in BRCA1. In addition, 
other diseases such as Fanconi Anemia arise from defects in the BRCA1-related 
pathways. 
4. Radiation therapy and many chemotherapy drugs act by causing DNA damage 
in the cells. BRCA1 is an important participant in the cellular response to DNA damage, 
which makes it very essential factor in determining the patient’s response to therapy in 
many cancers including lung and ovarian cancers [101, 102].  
 
The DNA Damage Response (DDR) Network 
 
DDR: DNA Repair and Cell Cycle Checkpoints 
 
In order to preserve genome integrity, different evolutionarily conserved DNA 
cellular processes such as the DNA damage response (DDR) and cell cycle checkpoints 
have evolved [103]. The DDR may be defined as a collective name for the processes, 
with the help of which cells detect DNA damage, initiate DNA repair, and coordinate 
repair with cell cycle progression. Therefore, the DDR is a complex network of different 
interconnected pathways. We arbitrarily divide the protein complexes involved in the 
DDR as sensors, signal transducers, effector kinases, mediators, and effector proteins [3, 
104]. Cell cycle checkpoints represent the mechanisms by which cells stop (during G1, 
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G2 phases) or slow down (during S-phase) cell cycle progression, until an earlier process 
such as replication or mitosis is completed [105]. After DNA repair is accomplished, 
cells either resume cell cycle progression or, if the damage cannot be repaired, 
permanently arrest, senescence, or die (apoptosis) [106].  
Mutations in ATM, TP53, NBS1, BRCA1, BRCA2, CHEK2, PALB2, BACH1, and 
other genes lead to an increased risk for the development of breast cancer if compared to 
the risk of the general population [1]. These proteins participate in the DDR network. 
NBS1, p53, BRCA1, BRCA2, CHK2, and ATM itself are substrates for the ATM kinase 
activity, when the cells experience DNA damage (Figure 2). Moreover, cells, lacking full 
length functional ATM, NBS1, and BRCA1, share similar phenotypes such as cell cycle 
checkpoint defects, radio sensitivity, increased chromosomal breakage, and failure to 
phosphorylate SMC1 (cohesin subunit) after IR [107]. It is currently unclear why 
mutations of genes, the products of which are operating in a conserved mechanism active 
in every cell, lead primarily to breast and/or ovarian cancer predisposition. 
Double strand break (DSB) repair can be achieved mainly by two mechanisms: 
non-homologous end-joining (NHEJ) and homologous recombination (HR) [106, 108] 
and (Figure 3). On one hand, NHEJ is dependent on DNA-PKcs, Ku86, Ku70, and DNA 
ligase IV [106]. It can be performed throughout all cell cycle stages and is error prone. In 
addition to NHEJ, there is a less studied Ku86 and DNA Ligase IV-independent 
alternative end-joining pathway [109]. On the other hand, DSB generated during S and  
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Figure 2. Breast cancer susceptibility gene products and the DDR pathway.In 
this simplified view ATM is activated by the presence of DSB and phosphorylate 
CHEK2, BRCA1, and TP53. Activated CHEK2 also phosphorylates TP53 and 
BRCA1. Note that BRCA1 and NBS1 contribute to the ATM activation and can 
function both upstream and downstream of ATM. Phosphorylation of these proteins 
is required for the efficient activation of various cell cycle checkpoints. BRCA2 
regulates the function of the human recombinase RAD51. PALB2 act as a bridge 
between BRCA1 and BRCA2. Another protein implicated in breast cancer 
predisposition, PTEN, mediates down-regulation of AKT. (Adapted from [1]). 
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Figure 3. DNA repair by homologous recombination and non homologous end 
joining. The main steps of the two repair mechanisms are shown. (Adapted from [3]). 
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G2 phases of the cell cycle are predominantly repaired by HR, because sister chromatids 
are available to serve as repair templates. HR requires processing of DSB to generate 
single stranded DNA (ssDNA). ssDNA fulfills two roles: activates the checkpoint kinase 
ATR and is the only substrate that allows Rad51 recombinase to be loaded onto 
chromatin. HR is an error-free repair pathway [106]. 
Every day our cells are exposed to different DNA damaging agents that originate 
from their own metabolism (reactive oxygen species) or from their surroundings 
(ultraviolet (UV) radiation, IR, and different drugs) [103]. Different agents cause 
different types of DNA damage [3]. In this dissertation, we focus on DNA damage 
caused by ionizing radiation (IR), which primarily leads to double strand breaks (DSB) 
[110]. In some cases, we use hydroxyurea (HU) and campthothecin (CPT). To cause 
DNA damage, HU blocks DNA replication by inhibiting ribonucleotide reductase. 
Further, stalled replication forks undergo irreversible collapse and/or are processed to 
DSB [111]. Another effect is caused by CPT, which is a Topoisomerase I inhibitor that 
generates replication-mediated DSB [112]. In the current study, we investigate the extent 
to which different signal transduction pathways are activated after treating the cells with 
IR, HU, or CPT. 
 
Sensors, Signal Transducing Kinases, Effector Kinases, and Effector Proteins 
 
Upon DNA damage, three signal transducing Ser/Thr kinases: ATM, ATR, and 
DNA-PKcs are rapidly activated and recruited to the damaged areas in the DNA [113]. 
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ATM and DNA-PKcs are mainly activated in response to DSB, whereas ATR is activated 
by ssDNA and stalled replication forks [113], which consequently generate ssDNA, 
coated with RPA [114]. Once at the proper place, the kinases relay the DNA damage 
signals by phosphorylating numerous downstream substrates. For example, ATR and 
ATM directly phosphorylate and activate the main effector kinases CHK1 and CHK2. 
Activated CHK1 and CHK2 kinases then regulate the function of effector proteins such 
as p53, E2F, and Cdc25 phosphatases, which in turn directly regulate cell cycle 
progression [115]. 
When DNA damage occurs, DSB are first recognized by the MRN 
(Mre11/Rad50/Nbs1) complex and the Ku70/Ku86 heterodimer [106], which are all 
considered sensors for DSB. In addition, the ssDNA and stalled replication forks are 
recognized by Rad9/Rad1/Hus1 complex (also known as the 911 complex) and the 
ATRIP/ATR complex [106]. It has been shown that conserved motifs in NBS1, Ku86, 
and ATRIP interact with and are responsible for chromatin loading of ATM, DNA-PKcs, 
and ATR respectively [113]. 
Even though ATM and ATR overlap in the phosphorylation of their substrates, 
there are differences in their relative contribution. This contribution depends on the type 
of the genotoxic stress [116]. For instance, cells, that over express a kinase-dead mutant 
of ATR, are hypersensitive to UV, HU, and IR, while ATM deficient cells are 
hypersensitive only to IR [116]. According to current models, it is accepted that ATM 
and ATR are activated by different DNA structures, rather than specific genotoxins [114]. 
Adding complexity to the DDR, these various DNA structures can be converted to one 
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another. For example, DSBs, generated after IR will primarily activate ATM. However, 
different enzymatic activities (nucleases, helicases, etc.) during the end processing of 
DSB after IR often generate ssDNA, coated with RPA, which subsequently activates 
ATR [117]. Furthermore, ATR is important for maintaining genomic integrity not only 
after genotoxic stress, but also during normal cell cycle progression. 
 
Checkpoint Mediators 
 
Mediators in the DDR are proteins that act directly downstream of the ATM and 
ATR kinases [118] such as MDC1, 53BP1, BRCA1, the MRN complex, Claspin, and 
MCPH1. Mediators have different roles in the DDR, e.g. control over localization, 
activation of other factors, and act as a scaffold for the assembly of protein complexes 
[118, 119]. As an example, we will briefly describe the signaling events that lead to the 
recruitment of BRCA1 to the sites of DSB after DNA damage (Figure 4). There, once 
recruited, BRCA1 can be visualized as discernible nuclear foci, called irradiation-induced 
nuclear foci (IRIF) [120-123]. 
 First, after the DNA damage occurs, one of the earliest targets of activated ATM, 
ATR, and DNA-PKcs is the histone H2A variant H2AX [124]. It is phosphorylated at a 
conserved Ser 139 residue on both sides of the DSB, creating a specialized chromatin 
domain [125]. H2AX phosphorylated at Ser 139 is also referred as γ-H2AX. Because of 
its location in the nucleosomes, γ-H2AX is the most widely used DSB marker in western 
blots and in immunofluorescence analysis of foci formation. Our own work, which is not  
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Figure 4. Current model for the BRCA1 recruitment to the IRIF. DSBs are 
recognized by the MRN complex, which recruits activated ATM to the DNA lesion. 
ATM phosphorylates H2AX (for simplicity nucleosomes are depicted as blue 
circles). MDC1 binds directly to the phosphorylated H2AX and recruits the 
ubiquitin ligase RNF8. RNF8 initiates histone ubiquitylation at the damaged sites. 
This chromatin modification allows the recruitment of BRCA1 to the sites of DSBs. 
27 
 
included in this dissertation, demonstrated the importance of H2AX post-translational 
modifications in the regulation of its own turnover, cell cycle, and apoptosis [126]. After 
the phosphorylation of H2AX, MDC1 is recruited to the DSBs. MDC1 possesses tandem 
BRCT domains that recognize and bind directly to γ-H2AX [127]. The  major function of 
MDC1 is to amplify H2AX phosphorylation by recruiting additional ATM molecules or 
by inhibiting γ-H2AX dephosphorylation [128]. Such amplification allows for the 
recruitment of additional DDR factors to the sites of damage, most of which can be 
visualized as IRIF [118].  
According to the current understanding, the next event in the recruitment at the 
sites of DNA damage is the interaction between the FHA domain of the E3 ubiquitin 
ligase RNF8 and phosphorylated MDC1 [129-131] (Figure 4). Once recruited to the 
DSB, RNF8 catalyses Lys 63-linked ubiquitination of histones and other proteins [130] 
[131]. Such ubiquitination of γ-H2AX stabilizes the recruitment of 53BP1 and BRCA1 at 
the DSB sites [128]. For example, a protein called Rap 80 possesses both a ubiquitin 
interacting motif and a coiled-coil domain. The Lys-63 ubiquitinated histones are 
recognized by the ubiquitin interacting motif of Rap80 [132] [133]. Furthermore, the 
coiled-coil domain of Rap80 directly interacts with the coiled-coil domain of Abraxas 
[133]. The recruitment of BRCA1 at the sites of DSB is mediated by the binding of its 
BRCT domains to the phosphorylated Abraxas [132] [133] (Figure 4). Once in the proper 
location at DSB chromatin, BRCA1 coordinates DNA repair, transcription, and cell cycle 
checkpoints by facilitating the phosphorylation of downstream substrates such as p53, 
NBS1, CHK1, and CHK2 in an ATM/ATR-dependent manner [134]. The mechanistic 
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details of how BRCA1 modulates the phosphorylation of such a large number of 
substrates are still unclear. Moreover, ATM and ATR kinases phosphorylate BRCA1 at 
the numerous sites, thus modulating BRCA1 activity.  Further, BRCA1 interacts with 
ATR partner, ATRIP [135], promoting ATR-dependent checkpoint functions. However, 
the mechanism described above is not the only one that leads to the recruitment of 
BRCA1 to the DSBs sites. Even in the absence of γ-H2AX/MDC1/Rap80/Abraxas 
mechanism, BRCA1 still localizes to the sites of DSBs [136].  
Finally, BRCA1 acts as a scaffold for the assembly of different complexes after 
DNA damage. It has been demonstrated that three major BRCA1-containing complexes 
are formed after IR: one that contains BACH1 and is involved in the intra-S-phase 
checkpoint, another, CtIP and MRN complex, that participates in the early G2/M 
checkpoint, and the third, BRCA2/Rad51 that is responsible for DNA repair by HR [137]. 
 
DDR: Spatiotemporal Regulation in Specialized Chromatin Domains 
 
In addition to the widely used classification of DDR participants such as sensors, 
mediators etc., Bekker-Jensen and colleagues divide DNA repair complexes into three 
groups, depending on their location related to the DSB: DSB-flanking chromatin 
(chromatin compartment), single stranded-DNA micro compartment, and repair 
complexes that do not show retention at the DSB [121]. DSB-flanking chromatin is 
occupied by groups of proteins that assemble on both sides of the DSB and can spread 
megabases from both sides of the break [121]. Proteins that localize to this compartment 
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are ATM, MRN complex, MDC1, 53BP1, and BRCA1. In addition, single stranded-
DNA micro compartment is occupied by the proteins such as the single strand DNA 
binding protein RPA, ATR, Rad51, BRCA2, MRN complex, and BRCA1. Finally, 
complexes that do not show retention at the DSB are DNA-PKcs, Ku70, Chk1, Chk2, 
and p53.  
These specialized chromatin domains perform different functions in DNA repair 
and checkpoint signaling. Importantly, the proteins that occupy the DSB-flanking 
chromatin can assemble during all cell cycle stages. Meanwhile, complexes that occupy 
the single stranded micro-compartment assemble in a cell cycle dependent manner only 
during S and G2 phases. MRN complex and BRCA1 have unique roles in DDR signaling 
and processing of DSB because they are the only proteins that can be found in two 
compartments (double and single stranded). This fact is essential when discussing 
dependence in the recruitment of different proteins to the DSB sites and their functional 
consequences. For example, the down regulation of MDC1 leads to the dissociation of 
BRCA1 only in the chromatin, but not in the single stranded compartment [121]. On the 
contrary, the down regulation of BRCA1 leads to the dissociation of BRCA2/Rad51 
complex from the single strand compartment, showing that BRCA1 is upstream of 
BRCA2/Rad51 in the DNA repair signaling. In addition, it has been proposed that 
different protein complexes contribute to the recruitment of BRCA1 to the different 
compartments [138]. For instance, MDC1/Rap80/Abraxas complex localizes BRCA1 to 
the chromatin compartment (see the previous section), and MRN complex and CtIP – to 
the single stranded DNA micro compartment. Most likely the disruption of BRCA1 
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function in these different locations will have different functional consequences for the 
DNA repair and checkpoint signaling. 
 
BRCA1: Structure and Functions 
 
The Structure of BRCA1 
 
The BRCA1 gene locus is located on chromosome 17q21 and codes for a 1863 
amino acids protein [13]. The conserved domains and motifs of BRCA1 are shown on 
Figure 5 and summarized in Table 3. At its N-terminus, BRCA1 has a zinc binding 
RING finger domain (aa 1-101) [13]. In vivo, most of BRCA1 resides in a complex with 
BARD1, which also contains a RING-finger domain [139, 140]. BRCA1 and BARD1 
interact with each other via their respective RING finger domains and form a stable 
heterodimer [141]. RING finger domains possess intrinsic E3-ubiquitin ligase activity 
[85]. Consistent with this, BRCA1/BARD1 complex has E3 ubiquitin ligase activity [85] 
[142, 143].  
Within the BRCA1 RING domain, cancer causing mutations lead to the 
abrogation of BRCA1 E3-ubiquitin ligase activity and fail to restore radiation sensitivity 
of a BRCA1-deficient cell line [143]. Moreover, BRCA1 variants at the N-terminus of 
BRCA1, which disrupt BRCA1 binding to the E2-enzyme, lead to the loss of ubiquitin 
ligase activity [84]. Thus, loss of ubiquitin ligase activity correlates with susceptibility to 
breast and ovarian cancer [84]. 
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Table 3. BRCA1 domains and motifs  
Domains and Motifs Amino acids Function Refs 
RING 1-101 E3-ubiquitin ligase [13] 
NES 81-89 Nuclear export [144] 
Motif 1 123-130 unknown [145] 
Motif 2 178-189 unknown  (studied in this thesis)   [145, 
146] 
Ser 308 308 Aurora A phosphorylation target  site [147] 
Motif 3 378-388 unknown [145] 
Motif 4 458-467 unknown [145] 
DNA binding region 452-1079 Binding to branched DNA [148] 
NLS 503-508, 651-656 Nuclear import [149] 
Motif 5 512-521 unknown [145] 
Motif 6 845-869 unknown (studied in this thesis)  [145, 
146] 
Ser 988 988 CHK2 phosphorylation target  site [150] 
Motif 7 1147-1153 unknown [145] 
Ser 1189 1189 Cdk1 phosphorylation target  site [151] 
Ser 1191 1191 Cdk1 phosphorylation target  site [151] 
Motif 8 1208-1228 unknown [145] 
Coiled-coil 1369-1418 PALB2 binding [145] 
Ser 1387 1387 ATM/ATR phosphorylation target  site, 
intra-S-phase checkpoint 
[152] 
Ser 1423 1423 ATM/ATR phosphorylation target  site, 
G2/M checkpoint 
[152] 
Ser 1497 1497 Cdk1/Cdk2 phosphorylation target  site,  [151, 
153] 
Ser1524 1524 ATM/ATR phosphorylation target site,  [154] 
Ser1572 1572 CK2 phosphorylation target  site [155] 
BRCT1 [N] 1650-1753 DNA damage signaling, transcription  [156] 
BRCT2 [C] 1760-1855 DNA damage signaling, transcription  [156] 
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Figure 5. Structure of BRCA1. RING and BRCT domains are shown in red boxes; 
Coiled-coil domain is depicted as a black box; NLS, nuclear localization signal;M2, 
Motif 2; M6, Motif 6; The regions of BRCA1 that have evolutionary conservation 
above 75% are shown on the blue scale bar (Adapted from [2]). 
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At its C terminus, BRCA1 has two BRCT domains in tandem [156]. The BRCT 
domain was first described in BRCA1 (BRCT stands for BRCA1-C terminal domain) and  
was found in several proteins such as MDC1, p53BP1, and DNA ligase IV, which all 
participate in DNA repair and checkpoint control [156] [157]. It has been shown that 
tandem BRCT domains bind phospho-peptides [158, 159]. In particular, the two BRCT 
domains of BRCA1 behave as one functional unit that binds to phosphorylated proteins 
with the consensus sequence pSer-X-X-Phe (where X is any amino acid) [160]. 
Moreover, BRCT domains are important for the functions of BRCA1 as a tumor 
suppressor. According to the genetic evidence, all mutations found in cancer patients, that 
lead to the truncation of BRCA1 BRCT domains confer a high risk for cancer 
development [161]. Thus, such mutations are currently classified as deleterious variants 
[80]. 
The remaining central region of BRCA1 between the RING and BRCT domains 
has not been studied in depth. However, this region of BRCA1 contains several 
significant features. They include nuclear localization (aa 503-508), nuclear export 
sequences (aa 81-99) [144, 162], the coiled coil domain, and BRCA1 aa 452-1079 region, 
important for binding to branched DNA structures [148]. The coiled-coil domain 
encompasses BRCA1 exons 12 and 13 (aa 1391-1424) (see 5) [94, 163]. It has been 
found to interact with two proteins: JunB [163] and PALB2 [164, 165]. Importantly, 
mutations within the coiled-coil domain found in breast and ovarian cancer patients 
modulate the ability of BRCA1 to activate transcription [75]. Moreover, mutations such 
as L1407P and M1411T, mapped to the BRCA1 coiled-coil domain, disrupt the binding 
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between BRCA1 and PALB2 and are defective in homologous recombination repair 
assays [164]. The evidence described above suggests a potential role of the coiled coil 
domain in tumor suppression. 
Furthermore, the biological role of some BRCA1 phosphorylation sites has 
already been studied. For example, BRCA1 double mutant Ser 1423Ala/Ser 1524Ala 
cannot rescue the radiation sensitivity of BRCA1 deficient cells, showing that these two 
sites are important for survival after IR [154]. In addition, phosphorylation of Ser 1423 is 
required for the IR-induced early G2/M checkpoint [152] and Ser 1387 – for the intra-S-
phase checkpoint activation after IR [166]. Finally, phosphorylation of Ser 988 was 
reported as important for the role of BRCA1 in homologous recombination repair [167] 
and in mitosis [168]. Importantly, only one of these sites, Ser 1524, has been found 
mutated in patients with breast and ovarian cancer. However, its association with cancer 
has not been determined [2]. 
Finally, nine additional conserved segments [94] [145] were revealed during the 
analysis at the conserved positions in BRCA1 orthologs. Such segments are called Motifs 
1 to 8, and the coiled-coil domain of BRCA1 is referred to as Motif 9. The contribution 
of these nine motifs to different BRCA1 functions is still under researched. Analyzing the 
function Motif 2 and Motif 6 is the main focus of this dissertation. 
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BRCA1: Biochemical Activities and Biological Processes 
 
BRCA1 participates in many biochemical activities and biological processes and, 
thus, has a pleiotropic role in the cell. In fact, there is often a confusion between 
BRCA1’s involvement in various activities and processes.  
First, BRCA1 participates in such central processes in the life of a cell as DNA 
repair, control of the cell cycle, transcription, and mitosis [169] (Figure 6). In addition, 
many biochemical activities, ascribed to BRCA1, including transcription activation and 
repression [79, 170], chromatin remodeling [171], and ubiquitination [4]. However, it is 
not clear, which of these functions and activities, alone or in a combination, contribute to 
BRCA1 role as a tumor suppressor. Though many of these BRCA1 functions and 
activities are not tissue specific, and BRCA1 is a ubiquitously expressed protein, it is not 
clear why individuals heterozygous for BRCA1 mutations develop mainly breast and/or 
ovarian cancer. Thus, understanding of BRCA1 biology is ultimately linked to our ability 
to provide risk assessment and better treatment options for the patients with BRCA1-
associated breast and ovarian cancer.  
Second, research on BRCA1 functions has shown that BRCA1 activities in the 
cell are regulated by different post-translational modifications such as phosphorylation 
[122], ubiquitination [172], sumoylation [173, 174], and interactions with close to 100 
different cellular proteins. Another level of such regulation happens when BRCA1 
expression is tightly controlled during cell cycle progression. For example, BRCA1 
protein level is low in G0 and G1 phases of the cell cycle and increases as cells enter S-
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phase [149, 175]. Furthermore, BRCA1 localizes to discrete nuclear foci (dots) during 
normal S-phase, but it re-locates to PCNA-containing replication foci after DNA damage 
[122]. 
Finally, BRCA1 participates in many aspects of DNA damage signaling pathways 
such as intra-S-phase checkpoint [107, 166] [152], G2/M checkpoint [176] [152], spindle 
assembly checkpoint [169, 177], end processing [178, 179], and DNA repair both by HR 
and NHEJ (Figures 3, 6, and Table 4 ). In this dissertation, we focus on the functions of 
BRCA1 in the DDR.  
 
G1 Checkpoint 
 
The signal transduction pathway, that is responsible for the cell cycle arrest in the 
G1 stage of the cell cycle includes, ATM, ATR, CHK2, CHK1, MDM2, TP53, and p21 
[103]. The ultimate goal of this pathway is to stop the cell cycle by increasing the 
stability and transcriptional activity of TP53 protein [103]. TP53 controls the expression 
of CDK inhibitor p21, which in turn inhibits the kinase activity of cyclin E/Cdk2 [103]. 
The main mediators of G1 checkpoints are the tumor suppressors TP53 and pRB. BRCA1 
has been implicated in interactions with both p53 and pRB, and it is thought that BRCA1 
participates in G1 checkpoint control by its numerous interactions with ATM, ATR, RB, 
p53, and p21 [180] [181]. However, the molecular details and the end point effects of 
BRCA1 deficiency with regard to G1 checkpoint are not clear.  
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Intra-S-Phase Checkpoint 
 
The intra-S-phase checkpoint is defined as the checkpoint ―activated by DNA 
double strand breaks that are generated in genomic loci outside the active replicons‖ 
[182]. For example, it can be triggered by the IR-induced DSBs. The activation of intra-
S-phase checkpoint leads to a rapid decrease in DNA synthesis after DNA damage 
because of the inhibition of new origin firing [115]. Cells with defective intra-S-phase 
checkpoint control fail to down-regulate DNA synthesis and display a radio-resistant 
DNA synthesis (RDS) phenotype [115, 182]. The RDS phenotype has been observed in 
cells deficient in proteins such as: ATM, ATR, CHK1, CHK2, NBS1, 53BP1, BRCA1, 
and BRCA2 [182]. This suggests these proteins' participation in the activation or 
maintenance of the checkpoint. Finally, it has been demonstrated that the intra-S-phase 
checkpoint is cooperatively controlled by at least two parallel ATM-dependent 
mechanisms: the ATM-NBS1-BRCA1-SMC1 [107, 182] axis and ATM-CHK2 -
CDC25A-Cdk2 axis [183] and (Figure 7).  
In the first pathway, ATM-dependent phosphorylations of SMC1 at Ser957 and 
966, NBS1 at Ser343, and BRCA1 at Ser1387 are necessary for the intra-S-phase 
checkpoint activation [152, 166]. However, it is not clear how phosphorylated SMC1 
leads to down regulation in DNA replication. In addition, the functional consequences of 
NBS1 and BRCA1 phosphorylations are poorly understood. To complicate this matter  
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Figure 6. Cell cycle stages and participation of BRCA1 in cell cycle checkpoints. 
G1, gap phase 1;G2, gap phase 2; S, DNA synthesis stage; M, mitosis. Participation of 
BRCA1 in different cell cycle checkpoints is shown with red arrows. (Adapted from 
http://homepage.mac.com/enognog/checkpoint.htm). 
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Figure 7. The intra-S-phase checkpoint signaling. The two parallel pathways that 
cooperatively control this checkpoint are depicted. (Adapted from [3]). 
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further, it has been demonstrated that the phosphorylations of BRCA1 at Ser1387 and 
NBS1 at Ser343 are not necessary for the ATM-dependent phosphorylation of SMC1 at 
the Ser 957 and 966 sites after IR. Instead, it has been hypothesized that BRCA1 and 
NBS1 might be needed as scaffold proteins in order for SMC1 phosphorylation to occur 
properly after DNA damage [184].  
According to the current understanding, the recruitment of BRCA1 and NBS1 to 
the DSBs happens independently of ATM phosphorylation. Moreover, the initial 
activation of ATM occurs independently from BRCA1 and NBS1 [107]. However, 
BRCA1 and NBS1 are required for the proper localization of once activated ATM to the 
break sites [107]. Only then, ATM can phosphorylate substrates such as BRCA1, NBS1, 
and SMC1. Moreover, BRCA1 and NBS1 phosphorylations are dependent on each other 
and on the proper ATM recruitment to the DNA DSB sites [107].  
The other signaling pathway, implicated in the intra-S-phase checkpoint, is ATM-
CHK2 -CDC25A-Cdk2 [183]. Signaling through this pathway leads to Cdc45 inability of 
being loaded at the replication origins. However, such loading is necessary for the  
initiation of DNA replication [183]. Interestingly, BRCA1 interacts with BACH1 helicase 
and TopBP1. BRCA1, BACH1, and TopBP1 appear to control Cdc45 origin-licensing 
factor after DNA damage through poorly understood mechanisms [137]. Thus, in 
addition to ATM-NBS1-BRCA1-SMC1 pathway, BRCA1 might also participate in the 
ATM-CHK2 -CDC25A-Cdk2 axis of the intra-S-phase checkpoint by controlling Cdc45. 
In conclusion, ATM initiates two parallel pathways that are responsible for the 
activation of intra-S-phase checkpoint by phosphorylating proteins such as CHK2, 
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BRCA1, NBS1, and SMC1. The examples discussed above illustrate the importance of 
BRCA1 in the regulation of different steps in DDR: functioning both upstream and 
downstream of ATM and acting as a scaffold for the assembly of multiple protein 
complexes. In addition to BRCA1, ATM, and NBS1, and another BRCT domain 
containing protein – DNA replication factor C has been purified as a part of a large super 
complex named BASC (BRCA1 associated genome surveillance complex) [185]. This 
shows a potential link between BRCA1 and replication-associated repair and signaling. 
Clearly, more research is necessary to elucidate mechanisms behind the complex role of 
BRCA1 in the intra-S-phase checkpoint. Any molecular details on this process will likely  
translate not only into better surveillance options for the patients with harmful BRCA1 
mutations, but also into designing improved treatments for cancer. 
 
G2/M Checkpoint 
 
ATM-CHK2 and ATR-CHK1 pathways control the checkpoint responses in the 
G2-phase of the cell cycle by phosphorylating the mitosis promoting phosphatase 
CDC25C (Figure 8). This phosphorylation inhibits the CDC25C, and it cannot 
dephosphorylate and thus activate cyclin B/CDK1 kinase complex [115]. Consequently, 
these events block the cells in G2/M phase of the cell cycle.  Moreover, the maintenance 
of the G2/M checkpoint relies on the transcription initiated by p53 and BRCA1. Thus,  
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Figure 8. The G2/M checkpoint signaling. Main sensor (911 complex), mediators 
(MDC1, BRCA1, and 53BP1), effector kinases (CHK1 and CHK2), and effector 
protein (Cdc25 phosphatase) are shown. (Adapted from [3]). 
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BRCA1 participates in G2/M checkpoint signaling via the transcriptional regulation (both 
activation and repression) of genes responsible for G2/M checkpoint control [186]. These 
genes include Cyclin B, 14-3-3 proteins, the Wee 1 kinase, and p21[186]. Finally, 
BRCA1 regulates the transcription of GADD45a [103], which in its turn regulates cyclin 
B/CDK1 kinase complex by the inhibition of its kinase activity [187]. 
However, besides its role in transcription, BRCA1 participates in the G2 phase 
checkpoint responses by being a target of ATM and ATR kinases. They both 
phosphorylate BRCA1 on multiple residues (see Table 2).  According to Kastan and 
colleagues, there are two distinct G2 checkpoints: early G2/M checkpoint and G2 
accumulation, which are measured by different methods and at different time points 
after IR [188]. Importantly, both checkpoints require BRCA1 participation [152, 188]. In 
particular, the expression of BRCA1 S1423A mutant in a BRCA1-deficient breast cancer 
cell line HCC1937 can reconstitute early G2/M checkpoint, but not G2 accumulation 
[188]. This indicates that the two checkpoints are controlled by different signaling events. 
The early G2/M checkpoint [188] occurs early after IR (1-2h) and is ATM- 
dependent. Furthermore, it occurs in cells in the G2/M boundary at the time of IR that fail 
to progress to mitosis [188]. On the contrary, the G2 accumulation checkpoint is dose-
dependent and ATM- independent [188]. It measures the cells that have been in S- and 
G1-stages at the time of irradiation. In addition, it represents these cells’ accumulation in 
G2 stage [188]. The G2 accumulation checkpoint is usually measured at a later time after 
IR (i.e. 24h). It is important to point out, that BRCA1- or NBS1- deficient cells, that have 
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a defect in IR-induced intra-S-phase checkpoint, usually display G2 accumulation 
phenotype [188]. 
Another checkpoint, called the Human decatenation checkpoint, can be related 
to the G2 checkpoint responses in the cell, although it is not a response to IR.  The 
Human decatenation checkpoint monitors chromatid decatenation in cells that progress 
from the G2 phase of the cell cycle to mitosis [189]. If sister chromatids are insufficiently 
decatenated, the progression from G2 phase to mitosis is blocked [189]. In particular, 
ATR and BRCA1 work together to control G2 decatenation checkpoint by excluding 
cyclin B1/Cdk1 complexes from the nucleus [189]. On the molecular level, BRCA1 
ubiquitinates topoisomerase II alpha and regulates its decatenation activity [190]. Finally, 
Human decatenation checkpoint seems to be independent of ATM [189].  
Importantly, failure in any given checkpoint by itself does not lead to radio 
sensitivity [188]. This can be exemplified by BRCA1 mutants, expression of which affect 
only one checkpoint function of BRCA1 and do not influence cells’ survival after 
irradiation [152, 166, 188]. For example, the expression of BRCA1 S1387A mutant 
reverses the early G2/M checkpoint defect but not the intra-S phase checkpoint defect 
[152, 166]. On the contrary, S1423A mutant reverses the intra-S checkpoint defect but 
not the early G2/M phase checkpoint defect [152]. Therefore, radiation sensitivity as a 
phenotype is not necessarily a consequence of the defective checkpoint signaling; rather 
it represents a more complex phenotype because of the failure in more than one stage in 
the DDR. Thus, the fact that cell lines that do not express functional BRCA1 have 
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severely compromised long-term survival after irradiation, illustrates that BRCA1 
functions on several stages in the DDR and performs multiple functions after IR.   
 
Spindle Assembly Checkpoint 
 
The spindle assembly checkpoint monitors the accuracy of chromosome 
segregation by preventing cells with misaligned chromosomes from exiting mitosis [180, 
191]. BRCA1 regulates the transcription of several spindle assembly checkpoint genes 
(including Mad2) [177, 180]. Mouse embryonic fibroblasts, isolated from Brca1
Δ11/Δ11 
mice, displayed chromosomal abnormalities (bridges and lagging chromosomes), which 
are hallmarks of spindle assembly checkpoint defects [177]. The studies of spindle 
assembly checkpoint related to BRCA1 in mammalian cells have been difficult because 
the inhibition or over expression of BRCA1 leads to cell cycle arrest or apoptosis [180]. 
 The down regulation of BRCA1 in human prostate cell line DU-145 (which 
expresses wild type BRCA1) and human breast cancer cell line MCF7 (hemizygous for 
wild type BRCA1 expression), followed by microarray analysis revealed that BRCA1 
controls the transcription of many genes that are required for mitotic progression [192]. 
Moreover, it has been demonstrated that checkpoint kinase Chk2 and its target BRCA1 
(phosphorylated at Ser 988) function independently of p53 and DNA damage in mitosis. 
Chk2 kinase and BRCA1 are required for normal progression of mitosis and, 
subsequently, maintaining chromosomal stability [168]. 
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DNA-Repair by HR 
 
HR is an error-free DNA repair mechanism, which uses the sister chromatid or 
less often the homologous chromosome as a repair template [193] and (Figure 3). 
BRCA1 participates in the regulation of HR. The research on such regulation involved 
the measurement of HR efficiency in BRCA1-deficient cell lines [194, 195], association 
of BRCA1 with other proteins participating in different stages of HR (see below), and the 
decrease of Rad51 foci formation in the absence of functional BRCA1 [121, 137, 196]. 
As an example, mouse cell lines, which do not express functional Brca1, have decreased 
HR efficiency and increased genomic instability [194, 195]. In addition, several BRCA1-
interacting partners participate in the control of HR repair. These include a growing 
number of proteins such as BRCA2 [4], PALB2 [164], BACH1 [197], CtIP [178, 198], 
53BP1, and the MRN protein complex [3, 198]. Several of these proteins function as 
enzymes, which facilitate HR repair. For example, the MRN complex [199] has nuclease 
activities and BACH1 [197] and BLM [200] are DNA helicases.  
The interaction of BRCA1 with PALB2 is of particular interest because the latter 
is also a breast cancer predisposition gene [164, 201-203]. Furthermore, biochemical 
studies on the BRCA1/PALB2 complex demonstrated that PALB2 not only binds to the 
coiled-coil domain of BRCA1 through its own coiled-coil domain [204], but also 
interacts with BRCA2 via the WD40 domain [205]. Thus, PALB2 interacts with both 
BRCA1 and BRCA2 and acts as a bridge between them [164, 205]. 
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Lastly, the participation of BRCA1 in the HR is demonstrated by the relation 
between BRCA1 and Rad51 recombinase. According to the current understanding, there 
is a hierarchy in the recruitment of the aforementioned proteins to the DNA damage sites. 
BRCA1 localization to the DSBs does not depend on PALB2, BRCA2, or Rad51 
recombinase. PALB2 is recruited to the sites of damage, at least in part, via its interaction 
with BRCA1 [193]. Furthermore, PALB2 interacts with BRCA2, the protein that loads 
the Rad51 recombinase on chromatin.  The role of BRCA2 in HR is a direct control of 
Rad51 nucleoprotein formation [206], while the role of BRCA1 seems to be more 
complex. BRCA1 functions earlier in HR and DNA damage checkpoint signaling by 
interacting with PALB2, BACH1, CtIP, and MRN complex.  
In addition to their role in HR, BRCA1, BRCA2, and PALB2 participate in the 
intra-S-phase checkpoint. Cells defective in the expression of these proteins do not have 
intact intra-S phase checkpoint [152, 205, 207]. Therefore, the intra-S-phase checkpoint 
is another possible process except for HR, in which the protein complex that consists of 
BRCA1, BRCA2, and PALB2 can potentially be involved. It is equally possible that 
BRCA1 participates in the intra-S-phase checkpoint signaling independently of BRCA2- 
PALB2 complex.  
At this stage, the mechanism by which BRCA1, BRCA2, and PALB2 carry out 
their tumor suppression activities is not clear. One possibility is that BRCA1 is localizing 
PALB2, BRCA2, and Rad51 at the DSBs, and, consequently, facilitating HR [121, 137]. 
Another possibility is that BRCA1, PALB2, and BRCA2 alone or in combination are 
responsible for the intact intra-S-phase checkpoint signaling. Finally, it may happen that 
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all of the above mentioned possibilities are working together. However, it is important to 
point out that the coiled-coil domain of BRCA1 seems to be necessary both for its role in 
HR [164] and for the intra-S-phase checkpoint function (Velkova and Monteiro 
unpublished results). 
In addition to PALB2, another important interacting partner of BRCA1, involved 
in the control of HR, is CtIP. In mammalian cells, CtIP is phosphorylated by CDKs, and 
it exists in a complex with BRCA1 in a cell cycle (during G2 phase) dependent manner 
[208]. Studies performed on the avian B-cell line DT40 demonstrated that CtIP 
participates in micro-homology directed end joining (during G1 phase) and in HR (during 
S and G2 phases) [178]. Importantly, the function of CtIP exclusively in HR is dependent 
on its interaction with BRCA1 [178, 208, 209]. Moreover, BRCA1  promotes CtIP 
ubiquitination and its localization to the sites of DSBs [210].  
Both CtIP and BRCA1 control RPA foci formation after DNA damage, thus 
controlling ATR activation [198, 209, 211]. In addition, BRCA1 co-localizes with the 
MRN complex at the IR-induced foci [120, 212] and inhibits its exo-nuclease activity 
[148], while CtIP stimulates the nuclease activity of the MRN complex [198]. Based on 
these data, it has been proposed that BRCA1/CtIP/MRN complex participates and 
controls the initial processing and/or resection of DSBs [138].  
Furthermore, BRCA1 might participate in the end-resection by its relation to 
53BP1. Only recently, the details about their role in the DDR became clear. Two recent 
papers explored the effect of 53bp1 deletion in Brca1-deficient mouse cells. In the first 
report, the deletion of 53bp1 rescues several phenotypes associated with Brca1 deficiency 
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such as the proliferation defect, hypersensitivity to DNA cross-linking agents, 
spontaneous formation of DSB, and activation of the DDR [213]. In the second report, 
53bp1 deletion rescues the HR defect of Brca1
Δ11/Δ11
 mouse cells by a mechanism 
dependent on ATM-controlled end resection [179]. Thus, it has been hypothesized that 
BRCA1 and 53BP1 might regulate the choice between HR and NHEJ [179], at least 
partially by their role in end-resection. The manner, in which BRCA1 in complex with 
CtIP, MRN, 53BP1,  or other proteins participates and controls end resection and DNA 
damage signaling remains obscure and is a subject for active research. 
Taken together, these data suggest that BRCA1 participates in HR by controlling 
protein localization and different activities during the end-resection step. Despite the 
evident contribution of the studies cited above, they should be interpreted with caution. 
The experiments described above have been carried out in avian B cell line DT40 (in the 
case of CtIP) and in mouse embryonic fibroblasts (in the case of 53BP1). DT40 cell line 
has a short cell cycle taken up mostly by S-phase and high levels of HR [108]. In 
addition, the survival of mouse embryonic stem cells is dependent on HR. However, the 
relative contribution of HR and NHEJ in repair and cellular responses to damage varies 
between species and in different cells [108]. Thus, the physiological importance of the 
effects of BRCA1 deficiency on breast and ovarian epithelial cells remains to be tested.  
 
 
 
 
50 
 
DNA-Repair by NHEJ 
 
NHEJ is considered to be the major DNA repair pathway responsible for fixing 
IR-induced DSB in mammalian cells [214]. It is operational throughout all cell cycle 
stages [214] and dependent on the Ku (Ku70/86) heterodimer, DNA-PKcs, XRCC4, 
DNA Ligase IV, Artemis, and XLF [214] (Figure 3). 
It is generally accepted that NHEJ has several stages: detection of DSB, end 
processing, and ligation [214]. In the process of detection of DSBs, the Ku heterodimer is 
the one recognizing the DSBs. Upon DNA damage, Ku86 interacts with a conserved 
motif on DNA-PKcs C-terminus, which leads to the recruitment of DNA-PKcs to DSBs 
and its activation [214]. Over 16 phosphorylation sites have been described on DNA-
PKcs, although their role is still poorly understood. Nevertheless, DNA-PKcs 
phosphorylation status is believed to influence its activity [215]. The unphosphorylated 
form of DNA-PKcs interacts with Ku86 [216]. Further, DNA-PKcs autophosphorylation 
is required for NHEJ progression and, subsequently, for end processing [217]. It has also 
been shown that Ku86 interacts with BRCA1 N-terminus, and this complex formation is 
necessary for the rapid recruitment of BRCA1 at DSB sites [218]. However, the 
downstream events in the DDR signaling, in which BRCA1 participates, are not clear.  
Furthermore, the reports for the role of BRCA1 in NHEJ have been conflicting 
(Table 4), ranging from no significant difference (slight elevation) to compromised 
NHEJ. However, the cited reports used different cell lines (mouse versus human, 
embryonic stem cells versus breast epithelial cells), which express various BRCA1 
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mutants such as the Δ11 isoform versus truncating mutation in HCC1937 cell line. 
Moreover, to measure the role of BRCA1 in NHEJ, different assays were used: from gene 
targeting and single chromosomal DSB at the specific position to plasmid-based in vivo 
and in vitro assays (Table 4).  In addition, plasmid-based assays account for the total end-
joining activity and do not discriminate between classical and alternative end joining. 
Thus, based on the available data, the role of BRCA1 in NHEJ regulation might be cell 
and DNA break type specific. 
 
Table 4. Comparison of different assays for BRCA1 repair function.  
Cell type Assay HR NHEJ Refs 
Mouse embryonic 
stem cells line 
236.44 
Gene targeting Decreased Proficient, Elevated [194] 
Mouse embryonic 
stem cells 
Gene targeting Decreased Increased [219] 
Mouse embryonic 
stem cell line 236.44 
I-Sce I induced 
chromosomal break 
Decreased Proficient, Elevated [194] 
Mouse embryonic 
stem cells 
Cell free assay-total end 
joining 
 Decreased [220] 
HCC1937 Plasmid base in vivo end 
joining 
 Decreased precise 
end joining 
[221] 
HCC1937 Plasmid base in vivo end 
joining 
 Decreased precise 
end joining 
[222] 
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Hypotheses for the Tissue Specific BRCA1 Functions 
 
Several hypotheses have been proposed to address the tissue specific functions of 
BRCA1. First, Scully and Livingston [223] hypothesized that some estrogen metabolites 
could potentially form DNA adducts. Specifically, breast and ovarian epithelial cells are 
estrogen-responsive. Thus, BRCA1 may play an essential role in the repair of estrogen-
induced DNA damage that cannot be compensated by other proteins.  
Second, Elledge and Amon [224] proposed a hypothesis, according to which the 
loss of BRCA1 as an essential gene has two different end results. In various tissues except 
for the breast and ovary, the loss of BRCA1 leads to cell death or proliferation defects. 
Nevertheless, in the breast and ovary, BRCA1-negative cells receive the necessary 
survival signals (hormones, growth factors, etc.) and continue to divide. This growth 
advantage increases the possibility of the secondary mutations to be accumulated over 
time, which in some cases will lead to the development of breast and/or ovarian cancer.  
In addition, Foulkes extended the Elledge and Amon’s hypothesis by proposing 
that BRCA1 functions as a major regulator for breast stem cells differentiation [225]. In 
this role, BRCA1 regulates differentiation of the breast epithelium. Failure in this 
regulatory mechanism results in loss of control over cell growth and potential block in the 
proper differentiation of the breast epithelial cells. This hypothesis explains some of the 
phenotypes of BRCA1-associated breast cancer (see pages 7-8).  
Finally, Monteiro proposed an alternative mechanism to explain the tissue 
specific tumor suppressor role of BRCA1 [226]. According to this hypothesis, BRCA1 
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locus is the subject to increased loss of heterozygosity rates only in the breast and ovarian 
epithelial cells, but not in the cells from the other tissues. Currently, none of these models 
has been experimentally tested and verified. 
 
Summary and Rationale 
 
Women who are carriers of deleterious mutations in BRCA1 are at a greater risk to 
develop breast and ovarian cancer than women from the general population. The 17 years 
after the cloning of BRCA1 have been fruitful for breast cancer research. The results from 
such research benefit patients not only when they make informed clinical decisions, but 
also when they undergo therapy for their BRCA1-related breast cancer. However, the 
experience from the bench and from the clinical practice shows that much more remains 
to be learned about BRCA1 and the mechanism through which it participates in one of the 
most universal processes in life — maintenance  of the genome stability.  
Considering that there are over 1500 alleles of BRCA1 in the human population, 
one of the most challenging tasks for genetic counseling remains to distinguish which are 
benign and which are cancer predisposing. Previous research has indicated that the 
likelihood of a BRCA1 variant being deleterious is higher when the variant is located in 
structurally and functionally defined protein domains such as the RING and BRCT 
domains. Consequently, the identification of other functional domains, besides the well-
studied ones, is critical for the understanding of BRCA1 function and for classifying 
variants as cancer predisposing or benign. To approach this problem, we formulate our 
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central hypothesis: poorly characterized, conserved domains in the central region of 
BRCA1 (Motif2, Motif 6, and coiled-coil domain) directly participate in the tumor 
suppression functions of BRCA1.  
This dissertation aims at testing our hypothesis and determining how specific 
domains and motifs of BRCA1 act to promote tumor suppression. In particular, we set 
out to determine the functional significance of the two poorly characterized domains of 
BRCA1. This is a step further in our long-term goal to understand the mechanisms, by 
which BRCA1 is required for maintaining genomic stability, and to use this information 
to develop a system of assays for testing the functional role of any mutation in BRCA1. 
Importantly, our research has much broader implications because the gene products 
involved in breast cancer seem to cluster around DNA damage response pathways. Thus, 
the understanding of BRCA1 role may have an impact on other forms of breast cancer, 
not attributable to germline mutations in BRCA1. Moreover, both radiation therapy and 
most of the drugs used for cancer treatment rely on introducing DNA damage in the cells. 
BRCA1 is the main participant in the cellular response to DNA damage, which makes it 
an important factor in determining the patient’s response to therapy. 
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MATERIALS AND METHODS 
 
Constructs and Cloning 
 
GST-fusion fragments of BRCA1 in the mammalian expression vector pEBG BF 
1-6 were a gift from Toru Ouchi. BRCA1 fragments BF1A (aa 1-70), BF1B (aa 71-140), 
BF1C (aa 1-101), BF1D (aa 141-240), BF1D1 (aa 160-190), BF1D2 (aa 190-210), 
BF1D3 (aa 160-210), BF1E (aa 241-324), and BF1F (aa 1-302) were obtained by PCR 
using pEBG BF1 as template. The PCR products were digested, cloned into pEBG 
vector, and sequenced. Construct BF1D Y179C was obtained by site directed 
mutagenesis using BF1D as template for the PCR reaction. FLAG FLNA-Bf was 
obtained by cloning a PCR fragment of Filamin A (FLNA, aa 2477-2647) in frame to 
FLAG in pCMV2-FLAG vector. 
 For the yeast two hybrid interactions assays BRCA1 Motif 6 fragment (aa 845-
869) was obtained by PCR and cloned in frame with the GAL4 DNA binding domain 
into pGBKT7 vector. Similarly, FLNA repeat 23/Hinge/repeat 24 (aa 2477-2647), FLNA 
repeat 23 (aa 2477-2516), FLNA Hinge (aa 2517-2549), FLNA repeat 23/Hinge (aa 
2477-2549), FLNA repeat 24 (aa 2550-2647), FLNA repeat 24 (aa 2517-2647) were 
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obtained by PCR and cloned in frame with GAL4 activation domain into pGAD 424 
vector. 
The constructs containing BRCA1 Motif 6 mutants: S864L, F861C, Q855P, 
R866C, and R866H were obtained by site directed mutagenesis using as a template for 
the PCR reaction pGBKT7 Motif6 (aa 845-869). The products were digested, cloned in 
frame with GAL4 DNA binding domain into pGBKT7 vector, verified by sequencing, 
and used for the transformation of yeast strain AH109. 
 
Yeast Two Hybrid Assays 
 
For deletion analysis the yeast two hybrid was performed using the 
MATCHMAKER Two-Hybrid System 3 (Clontech laboratories). In brief, pGBKT7 
Motif 6 and pGAD 424, containing FLNA deletion mutants were co-transformed in AH 
109 yeast strain. Transformations were plated on SD –Leu – Trp selective media to 
access the efficiency of the transformation and SD – Leu – Trp – Ade – His to map the 
minimal domain of FLNA necessary for binding to BRCA1. 
For the liquid culture growth assay the AH109 transformants were inoculated in 
liquid media lacking either leucine and triptophane (-leu,-trp, double selection) or lacking 
leucine, tryptophan, histidine, and adenine (-leu-trp-his-ade, quadruple selection). The 
vectors used for the expression confer growth in the absence of leucine (pGAD424) or 
tryptophan (pGBKT7). Samples were taken every two hours and quantified by 
spectrophotometer at a wavelength of 600nm. The growth on double selection was used 
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to ensure that the constructs tested are not toxic for the yeast. If any of the Motif 6 
constructs interact with FLNA construct activation of the expression of histidine and 
adenine will follow and the yeast will grow in media lacking histidine and adenine. 
 
Cell Lines and Transfections 
 
The FLNA-deficient M2 melanoma cell line and its isogenic cell line, A7, 
reconstituted with full length FLNA cDNA [227](gift from T. Stossel) was grown in 
MEM (Sigma) with 8% newborn calf serum (Sigma) and 2% fetal bovine serum (FBS; 
SAFC Biosciences, Lenexa, KS). A7 cells were grown in the presence of 0.2 mg/ml 
G418 (Fisher). HeLa (ATCC, Manassas, VA) was grown in DMEM with 5% FBS 
(Sigma). HCT116 (ATCC) was grown in McCoy’s with 10% FBS. 293FT (InVitrogen) 
cells were grown in DMEM media (Sigma) with 10% FBS. Tissue culture media was 
supplemented with penicillin and streptomycin. Transfections were performed using 
Fugene 6 (Roche) according to the manufacturer’s instructions. 
 
Antibodies 
 
The following antibodies, peptides, and beads were used: -BRCA1 mouse 
monoclonal antibody MS110 (Ab-1; Calbiochem; San Diego, CA) and SG11 (gift from 
D. Livingston); -Filamin A mouse monoclonal antibody PM6/317 (Chemicon 
International); -FLAG M2 mouse monoclonal antibody (Sigma); 3xFLAG-peptide 
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(Sigma); -GST goat polyclonal antibody (Pharmacia Biotech); GT-sepharose 4B beads 
(GE Healthcare); -Ku86 monoclonal antibody B-1 and -Rad51 rabbit polyclonal 
antibody H-92 (Santa Cruz Biotechnology, Inc., Santa Cruz, CA); -TP53BP1 mouse 
monoclonal antibody and -phosphoserine 343-NBS1 mouse monoclonal antibody 
(Upstate Biotechnology); -p34 RPA mouse monoclonal antibody Ab-1 and -DNA-
PKcs mouse monoclonal antibodies Ab-2 (Neomarkers, Freemont, CA); -phosphoserine 
2056 DNA-PKcs rabbit polyclonal antibody (Abcam, Cambridge, MA); -phosphoserine 
2609 DNA-PKcs rabbit polyclonal antibody (Novus Biologicals); -MDC1 (SIGMA); -
H2AX rabbit polyclonal;-H2AX; -phosphoserine 1981 ATM; -ATM; -ATR; -
phosphothreonine 68 CHK2; -phosphoserine 317 CHK1 (Cell Signaling); - actin 
(Sigma). Conjugates for immunofluorescence were Alexa fluor 488 or 555 Molecular 
Probes. 
 
Immunoprecipitation, Pull-Downs, Western Blot Analysis, and Densitometry 
 
Whole cell extracts were prepared by lyzing cells in a mild RIPA buffer (120mM 
NaCl, 50 mM Tris pH 7.4, 1% NP40, 1mM EDTA, protease inhibitors, 4 mM PMSF) 
lacking harsher SDS, sodium deoxycholate, and Triton X-100 detergents. The same 
buffer was used for immunoprecipitation. For high stringency immunoprecipitations the 
RIPA buffer was supplemented with 0.5 % SDS. Antibodies (1g) were pre-incubated 
with protein A/G agarose beads (Santa Cruz Biotechnology, Inc.), washed twice in RIPA 
buffer and incubated with the cell extracts overnight at 4°C. After incubation, the slurry 
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were pelleted by centrifugation (2,000 rpm) and washed twice by removing the 
supernatant. Sample buffer was added to the beads and boiled for 10 min. For GST-pull 
downs, cell extracts were incubated with GT-beads, washed in RIPA buffer, and boiled. 
Samples for western blot analysis were separated by SDS-PAGE and gels were 
electroblotted on a wet apparatus to a PVDF membrane. The PVDF membrane was 
blocked with 5% milk in TBS buffer containing 0.1% Tween (TBS-Tween) for 1h. The 
membrane was washed three times in TBS-Tween and the antibody was added in 0.5% 
milk in TBS-Tween. The membrane was washed three times in TBS-Tween and 
incubated with the appropriate conjugate. After final washes Blots were incubated with 
ECL (Millipore, Billerica, MA).  
Chromatin fractions were obtained by lyzing the cells with mild RIPA buffer and 
centrifuging at 14,000 rpm for 5 min. The pellet was then washed twice in mild RIPA and 
extracted with acid extraction buffer (0.5M HCl, 10% Glycerol, 100mM BME) and 
subsequently neutralized using 40mM Tris pH 7.4 with protease inhibitors and NaOH. 
Western blot data was quantified by densitometry using AlphaEaseFC v 3.1.2. Each lane 
was normalized using the corresponding loading controls and then expressed as a fold 
change relative to the untreated FLNA
+ 
cells in each blot.  
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Immunofluorescence 
 
For BRCA1 analysis cells were fixed with 4% formaldehyde for 5 min followed 
by 5 min incubation with 100% ethanol. Cells were permeabilized with 0.25% Triton X-
100 in PBS for 10 min, washed with PBS, and then blocked for 30 min with 5% BSA in 
PBS at room temperature (RT). After blocking, BRCA1 monoclonal antibody (SG11; 
kind gift from David Livingston) was added to 1% BSA in PBS for 1h RT. Cells were 
washed and goat -mouse Alexa Fluor 488 (Molecular Probes) was added for an 
additional 1h RT.  
For all other antibodies, cells were plated onto chamber slides and after 24h they 
were washed with cytoskeleton buffer (10mM HEPES/KOH pH 7.4, 300mM sucrose, 
100mM NaCl, 3mM MgCl2) and fixed with 4% formaldehyde for 30 min RT. For 
analysis of chromatin bound RPA cells were pre-extracted for 2 min on ice with 
cytoskeleton buffer supplemented with 0.5% Triton X-100 before fixation [228].  After 
fixation cells were permeabilized with 0.25% Triton X-100 in PBS for 5 min RT and then 
washed and blocked with 5% BSA in PBS for 30 min RT. Primary and secondary 
antibodies in 1% BSA in PBS were added for 1h each.  
Cells were washed and mounted with Prolong Gold medium (Molecular Probes). 
Images were taken on a Leica Confocal Microscope. For quantification of BRCA1 and 
Rad51 immunofluorescence foci approximately 100 cells were scored per each time 
point. Cells were scored as foci-positive if they presented with more than 10 foci per cell 
(an example can be found in Figure 34). For -H2AX and NBS-P-343 at least 50 cells per 
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time point were counted for each condition. Cells were scored as foci-positive if they 
presented with more than 20 foci per cell. A threshold of 20 foci was chosen based on the 
number of foci found in unirradiated samples using the described antibodies. 
Determination of foci number per cell was done using Definiens Developer XD 1.1 
(Definiens AD, Germany). A rule set was developed to segment nuclei based on the 
DAPI stain and then segment foci within the nucleus based on an intensity threshold.  
Representative results from at least two independent experiments are shown instead of 
statistical data on a small number of measurements with variability as recently 
recommended [229] .  
 
Comet Assay 
 
Comet assays were performed in neutral conditions using a comet assay kit 
(Trevigen, Gaithersburg, MD) according to manufacturer’s instructions. Briefly, cells 
were collected at the indicated time points, combined in low melting agarose (Trevigen, 
Gaithersburg, MD), spread over the comet slide area and allowed to set. Then, slides 
were immersed in lysis buffer for 30 min at 4°C. Electrophoresis was run in TBE buffer 
for 20min at 1V/cm voltage. Image analysis was done with Comet Analysis System 2.3.3 
software (Loats Associates Inc., Westminster, MD).  
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RESULTS 
 
Characterization of the Interaction between FLNA and BRCA1 
 
Identification of FLNA as a Binding Partner of BRCA1 Motif 6 in Yeast 
 
Our laboratory has focused on the systematic analysis of domains and motifs in 
BRCA1 as a means to understand its biochemical functions [81]. Here we analyzed a 
conserved region, called Motif 6, spanning amino acids 845-869, coded by BRCA1’s 
large exon 11 (Figure 5) [94, 145].
 
 
In order to identify interactors for the conserved Motif 6 of BRCA1 spanning 
amino acid residues 845-869 (Figure 9), we performed a yeast two-hybrid screening 
against a human mammary gland cDNA library. Two overlapping clones coding for 
human Filamin A (FLNA; OMIM # 300017), spanning amino acid residues 2443-2647 
and 2477-2647 (Figure 9), were identified.  This region includes repeat 23, the hinge 
region, and repeat 24 in the C-terminus FLNA (Figure 9) [230]. We mapped the minimal 
region of FLNA, which interacts with BRCA1 Motif 6, by testing binding of a series of 
FLNA deletion mutants (Figure 9). Only the fragment aa 2477-2647 was able to bind to 
BRCA1 Motif 6 (Figure 9). Interestingly, FLNA has been shown to interact with BRCA2 
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and to participate in the DDR [231-233]. Cells lacking FLNA exhibit prolonged 
checkpoint activation, leading to the accumulation of cells in G2/M after ionizing 
radiation [231]. 
 
Interaction between FLNA and BRCA1 in Mammalian Cells 
 
Next, we tested whether endogenous FLNA interacted with endogenous BRCA1 
in mammalian cells. Immunoprecipitation, using a specific monoclonal antibody against 
BRCA1, pulled down FLNA in HeLa and HCT116 cells (Figure 10). In addition, 
immunoprecipitation using an antibody against FLNA, was able to pull down BRCA1 
(Figure 10). Thus, BRCA1 and FLNA interact in vivo, and the interaction is mediated by 
the C-terminus of FLNA. 
Because FLNA and BRCA1 have been demonstrated to be primarily cytoplasmic 
and nuclear respectively, we biochemically fractionated HCT116 cells to determine in 
which subcellular compartment the interaction occurs (Figure 11). We found that FLNA 
is expressed in the nucleus and cytoplasm, and BRCA1 can be co-immunoprecipitated by 
FLNA in the nuclear fraction (Figure 11). We also determined that the interaction is 
direct as bacterially expressed GST-tagged BRCA1 (aa 141-302) can pull down 
bacterially expressed His-tagged FLNA C-terminus (Figure 12).    
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Figure 9. BRCA1 Motif 6 binds to Filamin A (aa 2477-2674) in yeast.  Top panel: 
Diagram showing a Filamin A dimer. Red box, Actin binding domain; blue box 
indicates the minimal region that interacts with Motif 6 of BRCA1. Note that this 
region contains the dimerization domain for two Filamin A subunits. Bottom panel: 
Yeast two-hybrid experiments testing Motif 6 interaction with Filamin A fragments, 
as well as positive (Large T and p53) and negative (FLNA and empty vector) controls. 
Smaller regions of FLNA such as repeat 23, hinge region, repeat 23 and hinge, repeat 
24, and repeat 24 plus hinge failed to interact indicating that both repeats and the 
hinge region are necessary for a stable interaction. 
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Figure 10. BRCA1 and Filamin A interact in mammalian cells. Upper panels, co-
immunoprecipitation of endogenous BRCA1 with FLNA in HeLa and HCT116 cells 
showing interaction of endogenous BRCA1 and FLNA. Lower panels, reverse 
reaction showing co-immunoprecipitation of endogenous FLNA with BRCA1. 
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Figure 11. FLNA interacts with BRCA1 in the nucleus. HCT116 cells were 
fractionated into nuclear and cytoplasmic fractions using PARP and Talin as 
controls, respectively. Top panel shows that BRCA1 can be immunoprecipitated 
using FLNA antibody in the nuclear fraction. 
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Figure 12. FLNA directly binds to BRCA1 in vitro. GST and GST-BRCA1 (aa 141-
302) were used in pull down in vitro assays. GST-BRCA1 but not GST can pull down 
bacterially expressed His-tagged FLNA C-terminal region. 
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BRCA1 Binding to FLNA is Mediated Primarily by BRCA1 Motif 2 not Motif 6 
 
We searched the Breast Cancer Information Core Database (BIC, 
http://research.nhgri.nih.gov/projects/bic) and identified five missense variants in BRCA1 
Motif 6 region: S864L, F861C, Q855P, R866C, and R866H. All five mutants were 
classified as VUSs. Next, we tested the extent to which the indicated variants interact 
with FLNA. We checked the ability of the yeast strain AH109 co-transformed with 
constructs, coding for FLNA and Motif 6 to grow on liquid media under stringent 
selection. If any of the Motif 6 constructs interacted with FLNA construct, the activation 
of histidine and adenine expression would follow, and the yeast would grow in media, 
lacking histidine and adenine.  In this experiment a strong interaction should have similar 
profile as the positive control. However, even the wild type Motif 6 did not display such a 
profile, indicating that  the interactions between FLNA and all Motif 6 constructs tested 
were relatively weak (Figures 13 and 14). This observation raises questions about the 
significance of the results obtained with the Motif 6 mutants. Thus, we hypothesized that 
other regions in BRCA1, besides Motif 6, might contribute to BRCA1 binding to FLNA. 
We co-expressed in-frame fusions of GST to deletion fragments of BRCA1 and a FLAG-
tagged FLNA fragment (aa 2477-2647) in 293FT cells (Figure 15) to assess each region’s 
contribution to binding.  
We immunoprecipitated FLAG-FLNA using -FLAG agarose beads, and the 
eluate with FLAG-peptide was separated by SDS-PAGE. Western blot against 
endogenous FLNA confirmed that FLAG-FLNA was properly folded, because FLAG-  
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Figure 13. Growth curve in medium lacking leucine and tryptophan. S.cerevisiae 
strain AH109 (Clontech) was transformed simultaneously with pGBKT7/Motif 6 
mutants (aa 845-869) and pGAD424/FLNA (aa 2477-2647) constructs. Growth curves 
in medium lacking leucine and tryptophan (-leu,-trp, double selection) are shown. OD600 
of the cultures (y axis) is plotted against time (x axis). Large T Antigen (aa 86-708) and 
p53 (aa 72-309) were used as a positive control and pGBKT7/Motif6+pGAD424 and 
pGAD424/FLNA+pGBKT7 as negative controls. The growth on double selection was 
used as a control to ensure that the constructs tested are not toxic for the yeast. 
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Figure 14. Interaction between pGBKT7 Motif 6 mutants (aa 845-869) and 
pGAD424 FLNA (aa 2477-2647) constructs. S.cerevisiae strain AH109 (Clontech), 
transformed with the indicated constructs, was grown in medium lacking leucine, 
tryptophan, histidine, and adenine (-leu-trp-his-ade, quadruple selection). OD600 of the 
cultures (y axis) is plotted against time (x axis). Large T Antigen (aa 86-708) and p53 
(aa 72-309) were used as a positive control and pGBKT7/Motif6+pGAD424 and 
pGAD424/FLNA+pGBKT7 as negative controls. Note that none of the yeast, 
transformed with the M6/FLNA constructs grew within the first 24 hours, indicating 
that the interaction between BRCA1 Motif 6 and FLNA is weak. 
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Figure 15. Expression of BRCA1 fragments in 293FT cell line. Left panel, diagram 
of deletion constructs used to map the BRCA1 interaction site to FLNA. RING, RING 
finger domain; NLS, nuclear localization signals; BRCT, BRCA1 C-terminal domains. 
Right panels, co-expression of GST-fragments of BRCA1 and FLAG-FLNA (aa 2477-
2647) in 293FT cells. Lower molecular weight band obtained in the empty vector (V) 
transfection corresponds to GST. 
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Figure 16. FLNA interacts with multiple sites in BRCA1. Co-immunoprecipitation 
of BRCA1 fragments (WB GST), endogenous BRCA1 (WB BRCA1) with FLAG-
FLNA (aa 2477-2647). Note that endogenous FLNA is also immunoprecipitated by 
FLAG-FLNA (aa 2477-2647) confirming it is in the native conformation (WB 
FLNA). Strong reactivity shown for GST BF1 is due to recognition to the GST-
BRCA1 fragment that contains the epitope for the antibody. 
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Figure 17. GST-pull down experiments show that GST-BRCA1 fragments 1, 3, 
and 4 can precipitate endogenous FLNA. Co-immunoprecipitation of BRCA1 
fragments (WB GST) and endogenous FLNA (WB FLNA). 
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Figure 18. FLNA binds to aa 141-240 in BRCA1. Upper panel, diagram of deletion 
constructs used to map the interaction site to FLNA. NES, nuclear export sequence 
(black boxes). Lower panels, FLAG-FLNA (aa 2477-2647) interacts strongly with 
GST-BRCA1 fragments BF1 (aa 1-324), BF1D (aa 141-240), and BF1F (aa 1-302). 
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Figure 19. FLNA binds to aa 160-190 in BRCA1. Upper panel, diagram of deletion 
constructs of fragment aa 141-240 used to map the interaction site to FLNA. The 
location of the missense variant Y179 is indicated. Middle left panel, FLAG-FLNA (aa 
2477-2647) co-immunoprecipitates with GST-BRCA1 fragments BF1D1 (aa 160-190) 
and BF1D3 (aa 160-210). V, GST; D1, GST-BRCA1 fragment BF1D1 (aa 160-190); 
D2, GST-BRCA1 fragment BF1D2 (aa 190-210); D3, GST-BRCA1 fragments BF1D3 
(aa 160-210). Bottom panel, control for expression levels. Middle right panel, GST-
BRCA1 fragments BF1D1 (aa 160-190) and BF1D3 (aa 160-210) can pull down 
endogenous FLNA. 
76 
 
FLNA contains the dimerization domain for two FLNA subunits (Figure 9). In addition, 
western blot against BRCA1 showed that FLAG-FLNA interacts with endogenous 
BRCA1 (Figure 16, left panel). Moreover, western blot against GST revealed the  
interaction of FLNA with different fragments of BRCA1 under low stringency (Figure 
16, left panel). Interaction with Fragments 1 (aa 1-324), 3 (aa 502-802), and 4 (aa 758-
1064) was detected even under high stringency conditions (Figure. 16, right panel). 
Reverse pull-downs of endogenous FLNA using GT-beads confirmed that the interaction 
is mediated by BRCA1 Fragments 1, 3, and 4 (Figure 17). In both experiments, BRCA1 
Fragment 1 showed the strongest interaction (Figures 16 and 17).  
Fragment 1 (aa 1-324) includes the RING finger (aa 1-101)
 
[13] and nuclear 
export signals (aa 22-30 and aa 81-99) [144, 234]. To determine whether the interaction 
was mediated by these motifs, we used deletion mutants of BRCA1 Fragment 1 (Figure 
18). Initially, we identified BRCA1 residues 141-240 as the interacting region to FLNA 
(aa 2477-2647) (Figure 18). Further mapping identified residues 160-190 as the minimal 
region required for binding (Figure 19). This region, called Motif 2, had been previously 
identified as a conserved motif in BRCA1 orthologs [94, 145].    
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BRCA1 Variant Y179C, Found in Breast and Ovarian Cancer Patients, Disrupts the 
Binding between BRCA1 and FLNA 
 
To assess whether BRCA1 and FLNA interaction might contribute to breast 
cancer, we searched the Breast Cancer Information Core database 
(http://research.nhgri.nih.gov/bic/) for variants in this region. Variant Y179C is a frequent 
missense change recorded in the database (BIC Database). The introduction of BRCA1 
Y179C mutant significantly reduced BRCA1 interaction to FLAG-FLNA aa 2477-2647 
and to endogenous FLNA (Figure 20, upper and middle panels), further demonstrating 
the specificity of the interaction. Because other regions in BRCA1 except for Motif 2 also 
contributed to the binding, we investigated whether the Y179C mutation would disrupt 
binding to FLNA in the context of full length BRCA1. The introduction of Y179C 
mutation significantly reduced the interaction in the full-length context as compared to 
wild type BRCA1 (Fig. 19, bottom panel). In summary, these experiments demonstrate 
that Motif 2 primarily mediates the interaction with FLNA. Taken together, these data 
raised the possibility that lack of FLNA might impair BRCA1 foci formation after DNA 
damage. Thus, the following experiments were directed at assessing the role of 
FLNA/BRCA1 interaction in the DNA damage response.  
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Figure 20. Introduction of BRCA1 Y179C mutation significantly reduces BRCA1 
interaction to FLAG-FLNA aa 2477-2647 and to endogenous FLNA. W, wild type 
GST-BRCA1 fragment BF1D (aa 141-240); Y, GST-BRCA1 fragment BF1D with 
Y179C mutation. Bottom panels, Introduction of BRCA1 Y179C mutation into a full 
length BRCA1 context significantly reduces interaction to endogenous FLNA. W, 
wild type full length BRCA1; Y, full length BRCA1 carrying a Y179C mutation.   
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Analysis of the DNA Damage Response Signaling in FLNA Positive and Negative 
Cell Lines 
 
FLNA Deficiency Does Not Cause a Defect in Sensing DNA Damage 
 
To further characterize the functional significance of FLNA/BRCA1 interaction, 
we obtained the M2 melanoma cell line, which lacks FLNA, and its counterpart A7, 
which was obtained by reconstituting M2 cells with full length FLNA cDNA [227]. First, 
we assessed the kinetics of DSB repair after IR. We irradiated or mock treated the FLNA
-
 
and FLNA
+
 cell lines and collected cells at several time points after IR. We monitored the 
presence of DSB with an antibody against histone H2AX phosphorylated at Serine 139 
(-H2AX), a marker for DSBs [125] . Whereas the FLNA+ cell line efficiently repaired 
DSBs, and by 8h after IR there was no detectable -H2AX (Figure 21), FLNA- cells had a 
sustained high level of -H2AX for up to 32h after IR. We confirmed this observation 
using Comet assays (Figure 22). 
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Figure 21. FLNA-null cells are deficient in DNA repair. FLNA
+ 
(A7) and FLNA
- 
(M2) cells were irradiated with 8 Gy or mock-treated (U) and harvested at the 
indicated time points. While FLNA
+
 cells repair most of the DSBs (as measured by -
H2AX) by 8h, FLNA
-
 cells show significant unrepaired DSBs even after 32h post-IR 
(Top panel). Bottom panel shows total levels of H2AX as a loading control. 
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Figure 22. Neutral comet confirms that FLNA-null cells are deficient in repair. 
FLNA
+ 
(A7) and FLNA
- 
(M2) cells were irradiated with 8 Gy or mock-treated (NO 
IR) and harvested at the indicated time points and comet assays were performed 
under neutral conditions. A two-tailed Student’s T test was performed and p values 
are shown for statistically significant differences. 
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Further, we assessed whether cells lacking FLNA had a compromised DNA 
damage signaling. Thus, we tested whether ATM and ATR were properly activated upon 
DNA damage. The phosphorylation of ATM S1981 was not compromised in FLNA
-
 cells 
(Figure 23, Top panels). Likewise, the phosphorylation of CHK2 T68 and CHK1 S317, 
markers of ATM and ATR activation respectively, did not show a defect (Figure 24). 
Surprisingly, we consistently observed higher levels of phosphorylation of ATM, CHK2, 
and CHK1 in cells lacking FLNA (Figures 23, 24), which indicated the upregulation of 
ATM and ATR signaling. These results confirmed the previous data by Meng et al [231], 
showing the sustained activation of CHK2 and CHK1 in FLNA-deficient cells following 
damage. 
 
The Defect in FLNA-Deficient Cells Is not Restricted to Ionizing Radiation 
 
To determine whether the repair defect we observed was restricted to double 
strand breaks caused by IR, we tested a panel of agents that cause DNA damage by 
different mechanisms. First, we tested Camptothecin (CPT), a specific topoisomerase I 
inhibitor, by incubating cells with the drug for 1h and then removing it. The cells were 
then collected at several time points after the drug removal. Similar to what was found 
with IR, we noted that at early time points FLNA
-
 cells displayed increased and sustained 
activation of ATM (Figure 25). CHK2 also retained high levels of phosphorylation up to 
6h after the drug removal in FLNA
-
 cells (Figure 25). Next, we investigated the 
phosphorylation status of DNA-PKcs at residues S2056 and S2609, which represent the 
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two main SQ/TQ clusters of phosphorylation [214]. Interestingly, while levels of 
phosphorylation in S2069 are similar in both cell lines, phosphorylation levels of S2056 
were markedly diminished in FLNA
-
 cells (Figure 25). In addition, we saw the increased 
and sustained phosphorylation of CHK1, an indirect measure of ATR activation, and 
persistent phosphorylation of NBS1 even at 6h time point after the drug removal in cells 
lacking FLNA (Figure 26). The phosphorylation of RPA, which can be seen as a slower 
migrating band above the main band (Figure 27), was also increased and sustained up to 
24h in FLNA
- 
cells.   
Further, we tested the effect of Hydroxyurea (HU), a replication inhibitor that 
targets ribonucleotide reductase, by incubating cells with the drug for 24h and then 
removing it. The cells were then collected at several time points after the drug removal. 
In general, we verified that FLNA
- 
cells, treated with HU, displayed the increased and 
sustained phosphorylation of CHK2, CHK1, NBS1, and RPA (Figures 28, 29). These 
data are consistent with the abnormal activation of the DNA damage checkpoint after 
CPT and HU treatments. 
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Figure 23. FLNA-null cells show no impairment in activating the DNA damage 
response. Top two panels, ATM activation as measured by phosphorylation of S1981 is 
not compromised in FLNA
- 
cells. Blot for total ATM is used as a loading control. Note 
significantly higher levels of pS1981-ATM in FLNA
- 
cells. Middle three panels, no 
significant difference was observed in levels of DNA-PKcs S2056 or S2609 
phosphorylation but recruitment of DNA-PKcs to chromatin is defective in FLNA
- 
cells. Bottom two panels, ATR presence in chromatin (CHR) is shown. Blot for ATR 
levels in whole cell lysates is used a loading control. 
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Figure 24. CHK2, CHK1, and NBS1 activation as measured by pT68-CHK2, 
pS317-CHK1, and pS343-NBS1, respectively is not compromised in FLNA
-
 cells. 
Note consistently higher levels of pT68-CHK2, pS317-CHK1, and pS343-NBS1 in 
FLNA
- 
cells. -actin is used a loading control.  
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Figure 25. Effects of the CPT treatment on the DNA damaging signaling in 
FLNA-deficient and proficient cell line-ATM, CHK2 and DNA-PKcs activation. 
Note increased phosphorylation levels of S1981 in ATM in earlier time points found 
in FLNA
-
 cells after Camptothecin (CPT) treatment (first panel). FLNA
- 
cells also 
displayed retention of phosphorylation of T68 in CHK2 even at 6h after drug removal 
(second panel). Levels of Ku86 were used as loading control (third panel panel). 
FLNA-deficient cells also display diminished levels of DNA-PKcs S2056 
phosphorylation (fourth panel) but not of S2609 (fifth panel). Total levels of DNA-
PKcs were used as loading control (sixth panel). 
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Figure 26. Effects of CPT treatment on the DNA damage response signaling in 
FLNA-deficient and proficient cell line-CHK1 and NBS1 activation. Levels of 
phosphoserine 317 in CHK1 progressively increase in FLNA
-
 remaining elevated 
even at 6h after drug removal (Top panel). Note also the retention of high levels of 
phosphorylation at S343 in NBS1 (middle panel). Levels of -actin were used as 
loading control (bottom panel). 
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Figure 27. Effects of CPT treatment on the DNA damage response signaling in 
FLNA-deficient and proficient cell line-RPA phosphorylation. Deficiency in 
FLNA lead to increased and sustained phosphorylation of chromatin bound RPA as 
measured by the slower migrating band of RPA (top panel). Levels of Histone 
H2AX are used as loading controls (bottom panel). 
89 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 28. Effects of HU treatment on the DNA damage response signaling in 
FLNA-deficient and proficient cell line-CHK1, CHK2 and NBS1 activation. 
Note increased phosphorylation levels of T68 in CHK2 found in FLNA
-
 cells after 
treatment with Hydroxyurea (first panel). FLNA
- 
cells also displayed retention of 
phosphorylation of S317 in CHK1 even at 6h after drug removal (second panel). 
Levels of Ku86 were used as loading control (third panel). FLNA
- 
also displayed the 
retention of high levels of phosphorylation at S343 in NBS1 in late time points 
(fourth panel). 
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Figure 29. Effects of HU treatment on the DNA damage response signaling in 
FLNA-deficient and proficient cell line-RPA phosphorylation. Deficiency in 
FLNA also lead to increased and sustained phosphorylation of chromatin bound 
RPA after Hydroxyurea treatment (top panel). Levels of Histone H2AX were used 
as loading controls (bottom panel). 
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FLNA Deficiency Impairs BRCA1 and Rad51 Foci Formation 
 
To determine whether the deficiency in repair was due to the defective 
recruitment of factors required for the DDR, we performed immunofluorescence analysis 
in non-irradiated or irradiated cells at 1h and 24h time points after IR. The accumulation 
of -H2AX and pS343-NBS1, early markers of DNA damage, was comparable in both 
cell lines at 1h time point (Figure 30). In order to determine if there were small 
differences, we quantified foci-positive cells (Figure 30, lower panel). The results were 
comparable in both cell lines at 0 and 1 h after IR, but FLNA-negative cells showed the 
increased number of foci-positive cells after 24h. Likewise, the recruitment of mediator 
proteins MDC1 and 53BP1 was also comparable at 1h time point (Figure 31). Finally, the 
repair factor RPA did not show any difference between the cell lines at 1h time point 
(Figure 32). Consistent with our western blot results (Figures 21 and 24) where we 
detected abnormally high levels of -H2AX, pT68-CHK2, and pS317-CHK1 at 24h time 
point, we detected persistent foci of -H2AX, pS343-NBS1, and RPA at 24h time point 
after irradiation only in FLNA-deficient cells (Figures 30, 31, and 32). Thus, the repair 
defect in FLNA-deficient cells was not due to a failure into initiating the DNA damage 
response. 
Next, we investigated the ability of BRCA1 and Rad51 to form IR-induced foci. 
The criteria for scoring cells as foci-positive and foci-negative are shown on Figure 34. 
The detailed analysis showed that FLNA-deficient cells are unable to efficiently form 
BRCA1 IR-induced foci as compared to FLNA-proficient cells (Figure 31, bottom panel). 
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Figure 30. FLNA-null cells show no impairment in recruiting DNA damage 
response factors to IR-induced foci--H2AX and NBS1.  Early markers of DNA 
damage -H2AX (red) and phosphoserine 343 NBS1 (green) form foci irrespective 
of FLNA status. Note maintenance of foci after 24h only in FLNA
- 
cells. Lower 
panels show quantification of foci-positive cells ( 20 foci). 
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Figure 31. Recruitment of DNA damage response mediator proteins 53BP1 
(red, top panel) and MDC1 (green, middle panel) and BRCA1 to foci. 
Recruitement of 53BP1 and MDC1 is comparable at early time points. BRCA1 foci 
formation was compromised in FLNA-deficient cells (lower panel). 
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Figure 32. Recruitment of RPA and Rad51 to IR induced nuclear foci. Recruitment 
of repair factor p34 RPA (green, top panel) did not show any difference between the 
cell lines at the early time points.  FLNA-deficient cells displayed a delayed kinetics of 
Rad51 foci formation (bottom panel). 
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Although Rad51 displayed a comparable initial response at 3h time point after IR, it 
failed to mount a response comparable to FLNA-proficient cells at 6h time point after IR. 
Rad51 presented a delayed kinetics of foci formation with the peak at 15h time point in 
FLNA-deficient cells (Figure 32, bottom panel). Taken together these data suggest that 
the compromised repair capacity in FLNA-deficient cells may, at least partially, be 
mechanistically tied to the inefficient HR. 
 
The Lack of FLNA Leads to the Accumulation of ssDNA after the DNA Damage 
 
During our analysis, we noted that RPA foci in FLNA-deficient cells were not 
only persistent 24h after the DNA damage, but also significantly larger (Figure 32). To 
determine whether the RPA foci were associated with chromatin, we pre-extracted cells 
with Triton X100 before fixation. This method has successfully been used to detect only 
tightly bound to chromatin fraction of RPA [235]. Interestingly, FLNA-deficient cells 
accumulate large chromatin-bound RPA foci, whereas FLNA
+
 cells present fewer and 
smaller chromatin-bound RPA foci at 24h time point after IR (Figure 33). While most 
FLNA
+ 
cells have recovered from G2/M arrest and represent an asynchronous population 
at 24h time point, most FLNA
-
 cells remain arrested in G2/M at 24h time point after IR 
[231]. Thus, these large tracts of ssDNA, found in FLNA
- 
cells, are unlikely to be due to 
the replication foci. 
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Figure 33. FLNA-deficient cells present with large chromatin-bound RPA foci 
at 24h after IR. Higher magnification of FLNA
+ 
and FLNA
-
 cells after 24h post-IR. 
Left panel shows FLNA
+
 cells stained for RPA (green). Middle panel shows FLNA
- 
cells stained for RPA (green). Note that nuclear foci are significantly larger than in 
FLNA
+
 cells. Right panel shows a blow up of the inset (white square in middle 
panel) with staining for DAPI (blue), RPA (green), and -H2AX (red). 
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Figure 34. Criteria for scoring foci positive cells. Examples of foci-positive cells for 
BRCA1 and Rad51. 
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Analysis of the Expression of BRCA1-Interacting Fragment of FLNA and FLNA-
Interacting Fragment of BRCA1 in FLNA Positive Cell Line 
 
Expression of BRCA1-Interacting Fragment of FLNA Phenocopies the Loss of FLNA 
 
To gain more insight into the mechanism by which FLNA participates in DNA 
repair, we transfected FLNA
+
 and FLNA
-
 cell lines with flag-tagged Filamin A aa 2477-
2647 construct (BRCA1-interacting fragment). For the sake of simplicity, we will refer to 
this FLNA BRCA1-interacting fragment as FLNA-Bf. At 24h post transfection, we 
irradiated cells with 8Gy IR and collected samples at different time points. The 
transfection of FLNA-Bf did not lead to the checkpoint recovery in FLNA
-
 cells as 
measured by the phosphorylation of CDC2 Y15 (Figure 35). Interestingly, transfection of 
the same fragment in FLNA
+
 cells led to a similar phenotype as that found for FLNA
-
 
cells as shown by phosphorylation of CDC2 Y15 and H2AX S139 (Figure 36). We also 
confirmed that expression of FLNA-Bf acts in a dominant negative fashion in a stable 
transfection context (Figure 37). We generated HCT116 cells stably expressing GFP-
FLNA-Bf or GFP alone that were mock-treated and irradiated. Cells expressing GFP-
FLNA-Bf retained high levels of phosphorylated H2AX up to 32h after damage while 
cells expressing GFP alone showed levels returning to unirradiated levels at 8h after 
damage (Figure 37). 
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Figure 35. Expression of BRCA1-interacting fragment of FLNA in FLNA
- 
is 
unable to reverse the checkpoint recovery defect. FLNA
- 
cells were transfected 
with an empty FLAG vector or a FLAG FLNA-Bf constructs. Cells were mock-
treated (U) or treated with 8 Gy IR and cells were collected at different time points. 
Expression of FLAG FLNA-Bf was unable to reverse the recovery defect. 
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Figure 36. Expression of BRCA1-interacting fragment of FLNA phenocopies 
loss of FLNA. FLNA
+ 
cells were transfected with empty FLAG vector or a FLAG 
FLNA-Bf constructs. Cells were mock-treated (U) or treated with 8 Gy IR and cells 
were collected at different time points. Cells expressing of FLAG FLNA-Bf 
displayed a phenotype similar to FLNA
- 
cells. 
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Figure 37. HCT166 cells stably expressing GFP FLNA-Bf display a phenotype 
similar to FLNA
- 
cells. . HCT116 cells were stably
 
 transfected with empty GFP 
vector or a GFP FLNA-Bf constructs. Cells were mock-treated (U) or treated with 8 
Gy IR and cells were collected at different time points. Cells expressing of GFP 
FLNA-Bf displayed a phenotype similar to FLNA
- 
cells. 
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Expression of BRCA1-Interacting Fragment of FLNA Phenocopies Loss of FLNA 
 
Next we asked whether expression of a GST-tagged BRCA1 FLNA-interacting -
fragment (BRCA1-Ff) could also lead to a dominant negative phenotype (Figure 38). In 
order to verify the specificity of the interaction we transfected a mutated BRCA1-Ff 
carrying the Y179C mutation and determined whether it lead to a dominant negative 
phenotype. Introduction of the Y179C mutation (Figure 19) significantly reduced the 
BRCA1-FLNA interaction. The wild type BRCA1-FLNA-Ff led to increased and 
sustained phosphorylation of CDC2 Y15 and H2AX (Figure 38) while the BRCA1-Ff 
Y179C (Figure 38) displayed a dominant negative effect that is intermediate between 
vector control (Figure 36) and the wild type construct (BRCA1-Ff; Figure 38). This 
intermediate effect could be due to the residual binding of BRCA1-Y179C mutant to 
FLNA. Alternatively, this could also be due to the inability of the mutant to disrupt the 
binding of FLNA to other regions of endogenous BRCA1 that participate in the 
interaction (Figure 16).  
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Figure 38. Expression of FLNA-interaction fragment of BRCA1 Y179C mutant 
does not phenocopy loss of FLNA. FLNA
+ 
cells were transfected with a GST 
BRCA1-Ff or a GST BRCA1-Ff Y179C. Cells were mock-treated (U) or treated with 
8 Gy IR and cells were collected at different time points. Only cells expressing of 
GST BRCA1-Ff but not GST BRCA1-Ff Y179C displayed a phenotype similar to 
FLNA
- 
cells, confirming that the effect is specific.  
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Analysis of the Effect of FLNA on DNA-PKcs and Ku86 Interaction 
 
FLNA is Required for Efficient Interactions Between DNA-PKcs and Ku86 
 
Our previous experiments demonstrated that FLNA
-
 cells display defective DNA 
repair, showed signs of compromised HR, and accumulated large tracts of ssDNA. 
Because mammalian cells also repair DSBs using non homologous end joining (NHEJ) 
we hypothesized that lack of FLNA also had an impact on the NHEJ pathway.  
First, we tested whether FLAG-FLNA aa 2477-2647 interacted with NHEJ 
factors. FLAG-FLNA aa 2477-2647 immunoprecipitated DNA-PKcs in 293FT cells 
independent of DNA damage (Figure 39). To determine whether FLNA was required for 
the stability of the Ku86/DNA-PKcs complex we performed immunoprecipitation 
experiments in FLNA
+ 
and FLNA
- 
cell lines in the presence or absence of irradiation 
(Figure 40). Interestingly, in FLNA
-
 cells Ku86 and DNA-PKcs complex formation was 
compromised in IR-treated and untreated cells (Figure 40).
 
  
Next we tested whether FLNA was required for Ku86 loading onto chromatin 
after DNA damage. Ku86 was efficiently recruited to chromatin upon DNA damage in 
the presence and absence of FLNA (Figure 41) while we detected DNA-PKcs in 
chromatin only in the presence of FLNA (Figure 23). Interestingly, loading of Ku86 onto 
chromatin persisted longer and with consistently higher levels in FLNA
- 
than in FLNA
+ 
cells (Figure 41).  
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Finally, we tested whether BRCA1 was required to stabilize the interaction 
between DNA-PKcs and Ku86. As a model for studying BRCA1 functions in mammalian 
cells often is used HCC 1937 cell line. HCC 1937 cell line was established from 24-year-
old breast cancer patient, who is a carrier of BRCA1 5382insC mutation [236] and does 
not express p53 due to acquired p53 mutation [236]. We examined BRCA1-deficient 
HCC1937 cell line
 
[236] and a HCC1937 derivative reconstituted with full length 
BRCA1 (gift from J. Chen). Complex formation between Ku86 and DNA-PKcs was not 
dependent on BRCA1 under IR-treated or untreated conditions (Figure 42).  
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Figure 39. FLNA interacts in vivo with DNA-PKcs. Upper pannel, 293FT cells 
were transfected with FLAG-FLNA aa 2477-2647 (F) or empty FLAG vector (V) and 
mock-treated or irradiated with 20 Gy. Cells were collected after 1h and 
immunoprecipitated using -FLAG antibody.  FLAG-FLNA aa 2477-2647 co-
immunoprecipitates DNA-PKcs in the presence and absence of IR. Lower panel, 
control for expression and the efficiency of the immunoprecipitation. 
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Figure 40. FLNA mediates DNA-PKcs interaction to Ku86. The interaction 
between DNA-PKcs and Ku86 is compromised in cells lacking FLNA. Left panel 
shows that levels of DNA-PKcs and Ku86 are similar in both cell lines and in the 
presence and absence of irradiation. Right panel shows that Ku86 and DNA-PKcs 
interact in FLNA
+ 
cells in the absence of damage and complex formation is 
significantly increased in the presence of irradiation. Complex formation in the 
presence and absence of IR is severely compromised in FLNA
- 
cells. 
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Figure 41. Loading of Ku86 onto chromatin after DNA damage is increased in 
FLNA
- 
cells. FLNA
+  
and FLNA
-  
cells were mock-treated (U) or treated with 8 Gy 
IR and cells were collected at different time points. FLNA
-  
 cells show increased 
amounts of Ku86 after IR. Histone H2AX levels are used as a loading control. 
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Figure 42. BRCA1 is not required for the stabilization of the interaction 
between DNA-PKcs and Ku86. HCC1937 (BRCA1-) and HCC1937-BRCA1wt 
(BRCA1+) were mock-treated or treated with 20 Gy IR and cells were lyzed after 
1h. DNA-PKcs co-immunoprecipitated with Ku86 independent of BRCA1 status. 
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Lack of FLNA Leads to an Increase in End Joining Activity 
 
Given the inability of DNA-PKcs to interact with Ku86 and thus to be efficiently 
loaded on chromatin we decided to assess in vivo end joining activity. In order to 
measure end joining we used the pGL2 plasmid that has a luciferase reporter gene driven 
by a constitutive promoter. First, we transfected FLNA
- 
and FLNA
+ 
cells with undigested 
pGL2 plasmid or digested with either HindIII, which cuts the plasmid between the CMV 
promoter and the reporter gene, or EcoR1, which cuts the plasmid within the luciferase 
gene. Luciferase activity obtained by transfecting with the digested plasmids was 
measured as a percentage of the activity obtained in cells transfected with the undigested 
plasmid. Luciferase activity obtained from the HindIII-digested plasmid reflects total 
end-joining activity, while that obtained from EcoR1-digested plasmid reflects precise 
end-joining activity. Intriguingly, FLNA
-
 displayed up to 4-fold higher total and precise 
end joining activity compared to FLNA
+ 
cells (Figure 43). In summary, lack of FLNA 
leads to an increase in end joining activity on an episomal template. 
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Figure 43. Lack of Filamin A leads to an increase in end joining activity. FLNA
-
 
and FLNA
+ 
cells were co-transfected with a digested or undigested luciferase 
reporter plasmid and an internal Renilla luciferase control. The reporter plasmid was 
either cut between the promoter and the reporter gene or inside the coding region for 
luciferase and recovered luciferase activity is a measure of total (left) or precise 
(right) end joining, respectively. On the X axis the relative liciferase units are 
depicted. 
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DISCUSSION 
 
In this work we shed light on the mechanism by which Filamin A (FLNA) is 
required for efficient DNA repair. Our data indicates that lack of FLNA impacts on both 
homologous recombination and non homologous end joining. FLNA is an actin-binding 
protein and its inactivation leads to an array of disorders such as otopalatodigital 
spectrum disorder, Melnick-Needles syndrome, and periventricular heterotopia [230]. 
Although of unclear significance, at least two families carrying germline mutations in 
BRCA1 have been shown to manifest ventricular heterotopia [237, 238]. FLNA interacts 
with a variety of proteins, including BRCA2 [233] and deficiency in FLNA leads to 
sensitivity to DNA damage and a defect in the recovery from G2 arrest [231]. Thus, we 
investigated further its role in the DNA damage response.  
FLNA binds BRCA1 using its extreme C-terminus which contains its 
dimerization domain. BRCA1 interaction with FLNA is mediated by a 30 amino acid 
region in the N-terminus of BRCA1 which contains a conserved domain called Motif 2 
[145]. Introduction of the Y179C mutation in Motif 2 significantly decreases the 
interaction. Analyses by the Align GV-GD method or by a yeast-based recombination 
assay suggest that Y179C may act as a deleterious mutation [87, 239]. On the other hand, 
this variant has been found co-occurring in trans with a known deleterious mutation, 
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which indicates that it is unlikely to have severe effects [90]. Thus, the Y179C may 
constitute a hypomorphic mutation with moderate effects on breast cancer predisposition. 
Of note, Motif 2 is close to the region that has been implicated in binding of BRCA1 to 
Ku86 [218].  
In order to dissect the molecular role of FLNA in the DDR we took advantage of 
a well-characterized genetically-defined system.  A melanoma cell line lacking FLNA 
was isolated and subsequently reconstituted with FLNA yielding a pair of cell lines in 
which the only difference is the presence or absence of FLNA [227]. When we irradiated 
FLNA
- 
and FLNA
+ 
cells, we noticed that FLNA
- 
took much longer to resolve DSBs 
(Figures 21, 22). To elucidate the mechanism underlying the repair defect we 
systematically investigated the proficiency of damage signaling in FLNA
- 
cells.   
Initially we investigated the recruitment and activation kinetics of the upstream 
kinases, as well as their downstream substrates after DNA damage. We found that FLNA 
deficiency led to the hyperactivation of ATM as judged by phosphorylation of ATM 
S1981 and CHK2 T68, surrogate markers of ATM activation [240-242]. Similarly, lack 
of FLNA also led to a hyperactivation of ATR, as measured by CHK1 S317 
phosphorylation, a marker for ATR activation [114]. Moreover, we also found sustained 
levels of phosphorylation of NBS1 S343 to be higher in FLNA
- 
cells. Although the role 
of NBS1 phosphorylation in the DNA damage signaling is poorly understood, it is 
generally thought to reflect ATM and ATR activation [199, 243]. We also determined 
that major mediator proteins BRCA1, MDC1, and 53BP1 formed IR-induced foci 
irrespective of FLNA status. However, BRCA1 foci formation was significantly impaired 
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in FLNA-deficient cells. In addition, Rad51 foci formation displayed a delayed kinetics 
in cells lacking FLNA. These data indicate that FLNA-deficient cells have impaired 
homologous recombination. Indeed, Yue et al. showed that FLNA-deficient cells have a 
reduced ability to repair I-SceI-induced DSBs [232]. 
During the course of our experiments we noticed a consistent increase in the 
number of FLNA
-
 cells displaying IR-induced RPA foci. These foci progressively 
increased in size at later time points after IR. RPA is a ssDNA binding protein and 
participates in DNA metabolism processes where there is generation of ssDNA such as 
replication, repair, and recombination [244, 245].
 
Phosphorylation leads to inability of 
RPA to associate with the replication centers and leads to the association with DNA 
damage-induced foci instead [246].
 
In addition, we also verified the retention of 
phosphorylated RPA in the chromatin-bound fraction of FLNA
- 
cells after treatment with 
CPT or HU. Consistently, we found more hyper-phosphorylated forms of RPA associated 
with chromatin in FLNA
- 
(Figures 27, 29). In addition, the hyper-phosphorylation of RPA 
persisted longer in FLNA
- 
(Figures 27, 29). Interestingly, lack of NHEJ proteins DNA-
PKcs and Ku86, which together with Ku70 form the active DNA-PK complex, leads to 
accumulation of ssDNA in S phase [247]. Thus, we further investigated how the lack of 
FLNA impacted on DNA-PK complex formation. 
Remarkably, Ku86 failed to interact with DNA-PKcs in the absence of FLNA. 
The reduced stability of the interaction is not due to Ku86 failure to load onto chromatin, 
as FLNA
- 
cells displayed sustained higher levels of chromatin-bound Ku86 than FLNA
+
 
cells after damage. Ku86 is one of the first molecules to bind DNA ends after DSBs 
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[214] and recruits DNA-PKcs via its C-terminus [113].
 
Taken together these results 
establish that lack of FLNA results in an unstable association of Ku86 and DNA-PKcs 
impairing the function of the complex. This impaired DNA-PK activity leads to a 
continuous build up of ssDNA and Ku86 on chromatin.   
Over 16 phosphorylation sites have been identified in DNA-PKcs although their 
role is still poorly understood. Nevertheless, DNA-PKcs phosphorylation status is 
thought to influence its activity [215]. DNA-PKcs interacts with Ku86 and free ends of 
DNA in an unphosphorylated form [216], and autophosphorylation is required for NHEJ 
progression [217]. Thus, we investigated the status of the two major phosphorylation 
clusters in DNA-PKcs, namely the 2056 and 2609 clusters. Cluster 2609 was consistently 
phosphorylated upon treatment with IR, CPT and HU irrespective of the FLNA status. 
However, phosphorylation of the 2056 cluster was significantly reduced in FLNA
- 
cells in 
CPT but not in IR or HU treatment indicating that there are damage-specific effects of 
DNA-PKcs phosphorylation. Nevertheless, the fact that DNA-PKcs is phosphorylated 
upon damage in the absence of FLNA suggests that DNA-PKcs is interacting with the 
Ku86/DNA complex albeit transiently. Alternatively, it is possible that phosphorylation 
of DNA-PKcs is not mediated by autophosphorylation at the synaptic complex but rather 
via hyperactive ATM and ATR in FLNA-deficient cells.   
We showed that FLNA and BRCA1 interact and that FLNA deficiency leads to a 
marked decrease in BRCA1 foci formation after damage. To investigate further the role 
of BRCA1 we tested whether expression of the BRCA1 FLNA-interacting fragment in 
FLNA-proficient cells could also act in a dominant negative fashion leading to a 
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phenotype similar to FLNA-deficient cells. Strikingly, expression of the BRCA1-Ff lead 
to a defect in DNA repair as judged by CDC2 pY15 and -H2AX markers. This effect is 
specific because expression of BRCA1-Ff containing a mutation that disrupts 
FLNA/BRCA1 interaction does not lead to the same phenotype. Taken together, these 
data establish that BRCA1 participates in the FLNA-dependent regulation of the DNA 
damage response.   
Our data shows that absence of FLNA leads to defective DSB repair. The defect 
is a combined result of compromised HR and NHEJ processes. At this stage we cannot 
distinguish whether FLNA-deficiency leads to a defective step that is common to both 
pathways or, alternatively, it impacts different steps in these pathways. In fact, the 
interplay between these two arms of the DNA repair process is not fully understood 
[178], in particular after IR, which generates an array of different DNA modifications. 
The observed phenotype is consistent with a model in which Ku86 recognizes and binds 
free ends of DNA, but in the absence of FLNA, fails to make a stable complex with 
DNA-PKcs. We propose that unstable Ku86/DNA-PKcs interaction results in impaired 
end processing, accumulation of ssDNA, and hyperactivation of DNA damage signaling.  
Repair via NHEJ can be arbitrarily divided into early (damage recognition and 
processing of non-ligatable ends) and late (ligation) stages [214]. DNA-PK has multiple 
functions and is essential for early and late stages of classical NHEJ in mammalian cells 
[214]. To determine whether the lack of FLNA also impacted on the late stages of NHEJ 
we transfected cells with cleaved plasmids, which are thought not to require extensive 
processing, to monitor precise and total end joining activity. Cells lacking FLNA 
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displayed a significantly increased end joining activity, indicating that FLNA is not 
required for the late stages of end joining. The increase in end joining activity could be 
due to the fact that deficient DNA-PK activity may lead to an unrepressed DNA ligase 
IV-independent alternative end joining pathway [248-250]. Alternatively, the failure of 
FLNA-deficient cells to promote stable Ku86/DNA-PKcs complex on chromatin may 
increase the availability of free DNA-PKcs to act on the plasmid template. Further 
research will be needed to discriminate between these possibilities. 
In addition, in FLNA-deficient cells BRCA1 displays impaired foci formation 
suggesting that FLNA also plays a role in stabilizing BRCA1 at the DSBs. BRCA1 
colocalizes with Rad50/Mre11/NBS1 complex at IR-induced foci [120, 212] and inhibits 
Mre11 exonuclease activity [148].Thus, the diminished amounts of BRCA1 at IR-foci 
may lead to an unregulated Mre11 exonuclease activity with formation of the observed 
extended tracts of RPA-coated ssDNA in FLNA-deficient cells (Figures 31, 32, and 33). 
BRCA1 has also been implicated in the regulation of Rad51 [251, 252],
 
although the 
mechanism by which it happens is obscure [253]. The kinetics of Rad51 foci formation in 
FLNA-deficient cells suggests that there is no problem in the initial recruitment to foci 
(see Figure 32, bottom panel, 3h time point). The extended plateau observed in Rad51 
foci (from 3 to 12h after IR) may indicate an accumulation of DSBs that do not fulfill the 
end processing requirements for efficient Rad51 loading. Although further research will 
be needed to test this proposed model, it provides a tractable system to dissect the 
interplay between different processes involved in DNA repair. 
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It is possible that FLNA provides a framework for the assembly of factors in the 
synaptic complex. While unrepaired DNA in yeast (which lacks recognizable DNA-PKcs 
and FLNA orthologs) migrates to so-called DNA repair centers [254], the picture is 
different in mammalian cells where broken chromosome ends are essentially immobile 
[255, 256].  It will be interesting to determine whether lack of FLNA affects the mobility 
of broken ends. 
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